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I Abbreviations 
ABαC Dominant brain isoform of protein phosphatase 2A 
AD Alzheimer's disease 
Adas-cog Alzheimer's Disease Assessment Scale-cognitive subscale 
ACT Alpha-1-antichymotrypsin 
APP Amyloid precursor protein 
Aβ Amyloid beta 
BACE β-site of APP cleaving enzyme 
BHMT Betaine homocysteine methyltransferase 
CAT Computed axial tomography 
CBS Cystathionine beta synthase 
CNS Central nervous system 
CSF Cerebrospinal fluid 
CV Coefficient of variation 
Cys Cystathionine 
DLB Dementia with Lewy bodies 
DTT Dithiotrilae 
FTD Frontotemporal dementia  
HCY Homocysteine 
HHCY Hyperhomocysteinemia 
HRP Horseradish peroxidase 
LCMT-1 Leucine carboxyl methyltransferase-1 
LC-Tandem-MS     Liquid chromatography tandem massspectrometry 
L-DOPA L-3,4-dihydroxyphenylalanine 
MCI Mild cognitive dysfunction 
Met Methionine 
MMA Methylmalonic acid 
MMSE Mini-mental state examination 
MRI Magnetic resonance imaging 
MS Methionine synthase 
MTHF Methylenetetrahydrofolate 
MTHR Methylenetetrahydrofolate reductase 
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m/z Mass-to-charge ratio 
NFT Neurofibrillary tangles 
n.s. Not significant 
PDD Parkinson's disease with dementia 
PHF Paired helical filaments 
PME-1 Protein phosphatase methylesterase-1 
PNF-H Phosphorylated neurofilament H 
PP2A Protein phosphatase 2A 
PPAR Peroxisome proliferator-activated receptor 
PPMT Protein phosphatase 2A methyltransferase 
PS1 Presenilin 1 
PS2 Presenilin 2 
P-tau Phosphorylated tau 
SAH S-adenosyl homocysteine 
SAM S-adenosyl methionine 
SD Standard deviation 
SPE Solid phase extraction 
TMB Tetramethylbenzidine 
tHcy Total homocysteine 
THF Tetrahydrofolate 
TNF-α Tumor necrosis factor alpha 
VaD Vascular dementia 
WML White matter lesions 
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II Summary 
Many studies show a significant relationship between elevated plasma total homocysteine 
concentration (tHcy) and age associated neurodegenerative diseases like dementia, but it is 
not yet possible to link these two causally because of study limitations and pending treatment 
studies. Plasma tHcy is a nutritional metabolic marker. Mild to moderate 
hyperhomocysteinemia (HHCY; tHcy 12-30 µmol/l) is an indicator for deficiencies in B-
vitamins (folate, B12, B6). HHCY is associated with elevated plasma concentrations of S-
adenosyl homocysteine (SAH). SAH is the demethylation product of S-adenosyl methionine 
(SAM) which functions as a methyl group donor. The remethylation of homocysteine (HCY) 
to methionine is an important source for the generation of SAM. A disturbed cellular 
methylation potential is one important pathomechanism in HHCY and plays an important role 
in the development of neurodegenerative disease. 
The goal of the study was to determine in vivo if HHCY leading to a disturbed methylation 
status is linked to neurodegenerative alterations. In this study we examined the effect of 
experimentally induced HHCY on accumulation of phosphorylated tau (P-tau) protein, 
phosphorylated Neurofilament H (pNF-H), tumor necrosis factor alpha (TNF-α), and protein 
phosphatase 2A (PP2A) activity adjusted for total PP2A protein level in rat cerebral tissue. 
We induced HHCY with a homocystine (1.7%) and a methionine (2.4%) enriched diet in 
Wistar rats. After euthanizing the animals, the brain tissue was extracted and the accumulation 
of P-tau protein was measured by immunofluorescence. Metabolites were measured by liquid 
chromatography tandem mass spectrometry (LC-Tandem-MS). Concentrations of pNF-H, 
TNF-α, and PP2A activity and level were measured in cerebral cortex extracts. Results were 
normalized for total protein. 
The in vivo study showed that plasma tHcy in Wistar rats increased by more than 10-fold 
after five months of the methionine and homocystine diets when compared to baseline 
concentrations. Furthermore the dietary intervention led to a reduced methylation status 
reflected by elevation of SAH concentration, as well as a significant decrease in SAM/SAH 
ratio in two different brain regions (frontal cortex and brain stem). Plasma concentrations of 
folate and vitamin B12 were significantly correlated to brain SAM/SAH ratio. We noted a 
considerably increased accumulation of P-tau protein in the cerebral frontal cortex of rats 
nourished with both of the HHCY inducing diets. P-tau accumulation in the frontal cortex was 
positively related to plasma tHcy and negatively related to folate concentration.  Folate status 
rather than activity of PP2A or level of PP2A in brain tissues was related to phosphorylated 
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protein forms like P-tau and pNF-H. TNF-α concentration in frontal cortex did not differ 
according to diet.  
Our study showed that methionine and homocystine treated diets fed to Wistar rats are 
strongly effective in inducing a pronounced experimental HHCY. Requirements and turnover 
of methyl groups were different according to brain region and may reflect different regional 
biochemical pathways. Plasma concentrations of folate and vitamin B12 were significantly 
correlated to brain SAM/SAH ratio proving that better B-vitamin status is directly related to 
better brain methylation status. The accumulation of P-tau protein in the rat brain was related 
to HHCY and enhanced folate consumption or requirement. Plasma folate was lowered by 
supplementation of methionine or homocystine, thus causing increased P-tau and pNF-H. The 
effect of the diet on P-tau and pNF-H seemed not to be explained by lower activity of the 
catalytic unit of PP2A or protein level of the enzyme. Low folate, hyperhomocysteinemia, 
hypomethylation in the brain caused hyperphosphorylation of functional proteins involved in 
neurodegeneration. TNF-α in cerebral cortex does not explain HCY neurotoxicity in our 
study. 
These results must be verified in further studies examining the exact neurodegenerative 
mechanisms. In addition, it must be determined what effect mild to moderate HHCY, over a 
considerably longer period of time, has on P-tau, pNF-H, and PP2A activity. Because our 
study cannot be directly extrapolated to humans, it would be interesting to explore the effect 
of treatment with B-vitamins, leading to an improved methylation status, on concentration of 
P-tau protein, pNF-H, and PP2A activity and to test if this treatment has a direct impact on the 
cessation or delay of demential development.  
- 7 - 
 
Zusammenfassung 
 
In vielen Studien zeigt sich eine signifikante Beziehung zwischen einem erhöhten 
Plasmaspiegel an Gesamthomocystein (tHcy) und altersassoziierten neurodegenerativen 
Erkrankungen, insbesondere Demenz. Jedoch kann man bisher noch nicht von einer kausalen 
Beziehung sprechen wegen Studienlimitationen und ausstehenden Therapiestudien. Plasma 
tHcy ist ein metabolischer Marker, der sich  ernährungsabhängig verhält. Milde bis moderate 
Hyperhomocysteinämie (HHCY; tHcy 12-30 µmol/l) ist ein Indikator für B-Vitaminmangel 
(Folat, B12, B6). HHCY steht im Zusammenhang mit einer erhöhten Plasmakonzentration an 
S-Adenosylhomocystein (SAH), wobei SAH das Demethylierungsprodukt von S-
Adenosylmethionin (SAM) darstellt, welches als  Methylgruppenspender fungiert. Eine 
entscheidende Quelle der SAM-Bildung ist die Remethylierung Homocysteins (HCY) zu 
Methionin. Ein gestörtes zelluläres Methylierungspotential ist ein grundlegender 
Pathomechanismus bei HHCY und spielt für die Entwicklung neurodegenerativer 
Erkrankungen eine wichtige Rolle. 
Das Untersuchungsziel bestand in der Aufklärung, ob in vivo HHCY, die zu einem gestörten 
Methylierungsstatus führt, in Verbindung mit neurodegenerativen Veränderungen steht.  In 
dieser Studie untersuchten wir die Wirkung experimentell induzierter HHCY auf die 
Anreicherung von Tau-Protein (P-Tau), phosphoryliertem Neurofilament H (PNF-H), 
Tumornekrosefaktor (TNF-α) und Protein-Phosphatase 2A (PP2A) Aktivität und Level im 
Rattengehirn. 
Durch eine mit Homocystin (1,7%) und eine mit Methionin (2,4%) angereicherten Diät 
konnnten wir bei Wistar-Ratten eine HHCY erzeugen. Nach Euthanasieren der Tiere wurde 
das Gehirngewebe entnommen und die Akkumulation von Tau-Protein mittels 
Immunfluoreszenz untersucht. Die untersuchten Metabolite wurden mittels 
Flüssigkeitschromatografie-Tandem-Massenspektrometrie (LC-Tandem-MS) bestimmt. 
Konzentrationen von PNF-H, TNF-α und PP2A Aktivität und Level wurden im Extrakt des 
Rattengehirns bestimmt. Ergebnisse wurden normalisiert für Gesamtprotein.  
Unsere in vivo Studie zeigt, dass Plasma tHcy bei Wistar Ratten sowohl bei einer mit 
Methionin wie auch mit Homocystin angereicherten Diät im Zeitraum von fünf Monaten um 
mehr als das 10-fache ansteigt. Darüber hinaus führte diese diätetische Intervention zu einem 
Anstieg der SAH-Konzentration im Gehirn, sowie zu einer signifikanten Erniedrigung des 
SAM/SAH Quotienten in zwei verschiedenen Gehirnregionen (Frontaler Kortex und 
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Hirnstamm). Folsäure und Vitamin B12 Plasmakonzentrationen korrelierten signifikant mit 
dem SAM/SAH Quotienten. Wir beobachteten bei den Ratten unter Methionin und 
Homocystin angereicherten Diäten eine deutliche Verstärkung der  phosphorylierten Tau-
Proteinfärbung im frontalen Kortex. Die Anreicherung von P-Tau im frontalen Kortex stand 
in positiver Beziehung zum Plasmaspiegel von tHcy und in negativer Beziehung zur 
Folsäurekonzentration im Plasma. Der Folsäure Status der Ratten im Plasma stand eher in 
Beziehung zu phosphorylierten Proteinformen wie P-tau und PNF-H als die PP2A-Aktivität 
oder –Level. Konzentrationen von TNF-α im frontalen Kortex unterschieden sich nicht in 
Bezug auf die diätetische Intervention.  
Unsere Studie belegte, dass Methionin und Homocystin angereicherte Diäten in Wistar Ratten 
eine ausgeprägte experimentelle HHCY hervorrufen. Der Bedarf und Umsatz von 
Methylgruppen unterschieden sich in Anhängigkeit von der Gehirnregion und könnte 
regionale Unterschiede in biochemischen Stoffwechselwegen wiederspiegeln. Folsäure und 
Vitamin B12 Plasmakonzentrationen korrelierten signifikant mit dem SAM/SAH Quotienten 
und beweist hiermit, dass ein verbesserter B-Vitamin Status direkt mit einem verbesserten 
zerebralen Methylierungsstatus zusammenhängt. Die Anreicherung von P-Tau-Protein im 
Rattengehirn stand im kausalen Zusammenhang mit HHCY und erhöhtem Folsäurebedarf 
oder –umsatz. Folsäure Plasmaspiegel wurden erniedrigt durch den Zusatz von Methionin und 
Homocystin und korrelierte mit vermehrtem P-Tau und PNF-H. Die Auswirkung der Diät 
schien nicht erklärbar durch eine verringerte Aktivität oder Level der katalytischen Dimer-
Untereinheit des PP2A Enzyms. Niedriger Folsäurestatus, Hyperhomocysteinämie und 
Hypomethylierung im Gehirn scheint Hyperphosphorylierung von funktionellen Proteinen zu 
verursachen, die bei Neurodegeneration involviert sind. TNF-α im frontalen Kortex erklärt die 
neurotoxische Wirkung HCYs nicht.  
Diese Ergebnisse müssen in weiterführenden Untersuchungen, die exakten 
neurodegenerativen Mechanismen betreffend, bestätigt werden.  Außerdem sollte man 
Auswirkungen auf P-Tau, PNF-H und PP2A Aktivität untersuchen, wenn eine milde bis 
moderate HHCY über deutlich längeren Zeitraum aufrechterhalten wird. Da unsere Studie 
nicht direkt auf den Menschen übertragen werden kann, wäre es interessant in klinischen 
Studien die Wirkung einer Behandlung mit B-Vitaminen, insbesondere Folsäure und somit 
eines verbesserten Methylierungsstatus auf die Konzentration von phosphoryliertem Tau-
Protein, PNF-H und die PP2A Aktivität zu testen und ob diese Behandlung eventuell einen 
direkten Einfluss auf das Aufhalten oder Verzögern einer dementiellen Entwicklung hat.  
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III Introduction 
Approximately 4.5 million new cases of dementia are predicted worldwide for each year. The 
world’s population is aging; the prevalence of dementia will increase considerably in the next 
40 years when the world will be dealing with more than 110 million patients with dementia 
(38). The risk of developing dementia, a form of neurodegeneration, is strongly age-related. 
However, dementia explicitly is not an obligatory part of aging but is a true disease. There are 
different forms of dementia each having different pathomechanisms. In Alzheimer’s disease 
(AD) tau becomes hyperphosphorylated (P-tau) and aggregates into paired helical filaments 
(PHF) which accumulate in neuronal cell bodies as neurofibrillary tangles (NFT), these 
correlating with cognitive deficits, neurodegenerative disorder, and dementia. Vascular 
Dementia (VaD) is understood as a heterogeneous syndrome in which the underlying cause is 
a form of cerebrovascular disease such as multi-infarct dementia. Dementia is caused by 
several genetic and non-genetic risk factors. Many cross-sectional studies and prospective 
studies (46;112;132;146;165;181) on more than 10,000 subjects have shown significant 
associations between cognitive deficit or dementia and homocysteine (HCY) and/or B-
vitamins. Different mechanisms have been proposed to account for these associations, but a 
definite causal pathway has yet to be shown. Hyperhomocysteinemia (HHCY) has been 
linked in many studies to diseases of the central nervous system (CNS). It is an important goal 
to find prognostic markers allowing early detection of disease or populations at risk for 
dementia. Raised plasma total homocysteine (tHcy) is a strong prognostic marker of future 
cognitive decline and dementia, and is common in world populations. Low-normal 
concentrations of the B-vitamins, the main determinant of HCY concentrations, are also 
common and occur in particularly susceptible phases in life, such as in infancy and at a more 
advanced age. An improved pathobiochemical understanding of effects of HHCY on 
hypomethylation and hyperphosphorylation will aid in developing strategies for early 
prevention. A decrease in the risk for the development of neurodegenerative diseases by 
lowering the concentration of tHcy by sufficient alimentary vitamin supply or 
supplementation in the case of vitamin deficiencies was shown in some studies (13;30;195) 
but not in others (103) and needs to be evaluated further. Research at this time calls for large-
scale multi-centered randomized trials of HCY-lowering vitamins to see if a proportion of 
dementia in the world can be prevented. 
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1 Dementia, an Age-Associated Neurodegenerative Disease 
Neurodegeneration is a term used to describe the process of pathological and destructive 
changes occurring in the brain. Neurodegenerative diseases include a wide group of disorders 
of various etiologies and clinical features and are mostly present in the second half of life and 
probably take decades to develop. They all have in common structural and functional protein 
modifications, resulting in deterioration of certain nerve cells or neurons. The clinical 
correlate of age-related neurodegeneration is cognitive decline and can lead to dementia. Mild 
cognitive impairment (MCI) represents the intermediary stage between normal aging and 
dementia. MCI is an age-dependent disorder characterized by impairment of memory and/or 
another cognitive domain. This reduction of previous level of function is by definition not 
severe enough to interfere with daily function, independence, social, or professional abilities. 
However, compared to people without memory decline, patients with MCI, older than 65 
years, have a risk of 10-15%/year to develop dementia in comparison to the healthy 
population with a risk of 2%/year (28;155). Understanding this is essential in order to identify 
risk factors and markers for the development or progression of MCI and/or dementia. 
Identifying extrinsic factors that accentuate the effects of aging and eliminating these, would 
then lead to successful aging, in which extrinsic factors play a neutral or positive role. HHCY 
is an example for a prognostic marker; an inverse relationship has been shown for cognitive 
function. Studies have shown HHCY to accelerate the progression of mild cognitive 
impairment to dementia as in this recent study where tHcy measured at baseline predicted the 
rate of cognitive decline in patients with AD (137).  
 
1.1 Epidemiology of Dementia 
A very high proportion of elderly people develop dementia and the probability increases with 
age. Worldwide prevalence of dementia is strongly related to age: 0.5% in those between 60 
and 65 years, 1.5% between 65 and 69 years, 3% between 70 and 74 years, 6% between 75 
and 79 years, 12% between 80 and 84 years, and 25% in those aged 85 to 89 years. The 
prevalence reaches almost 50% in those over 95 years (42). Figure 1 demonstrates how 
prevalence of dementia according to age in Germany increases approximately by two-fold 
every 5 years after the age of 65 years. Although the development of dementia is strongly age-
related, dementia is not an inevitable part of aging. It is a true disease caused by exposure to 
genetic as well as non-genetic risk factors.  
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The world prevalence of dementia for the year 2000 was estimated at 25.5 million by Wimo et 
al. (204). The authors estimated that in the year 2000 numbers for dementia were 11.9 million 
in Asia, 7.4 million in Europe, 3.1 million in North America, 1.7 million in Latin America, 
1.25 million in Africa. However, the number for North America may have even been 
estimated rather low since for the U.S. alone there was an estimated 4.5 million Americans 
with AD (65). AD is the most common form of chronic dementia but accounts only for 60 to 
80 percent of dementias.  
Due to the predicted demographics showing a steady percentile increase of the elderly 
generation, the prediction of future worldwide prevalence for dementia suggests that there 
may be as many as 114 million patients with dementia by the year 2050. The Delphi 
consensus study (38) largely is in agreement with these predictions Wimo et al. (204) made 
and estimated that each year there will be 4.5 million new cases of dementia worldwide. 
Another concerning feature of the worldwide prevalence estimates is that, in 2000–2001, 52% 
to 60% of those with dementia lived in less-developed regions (38), by 2050 there will be as 
many as  74% (84 million) living in the less-developed regions (204). These alarming 
predictions for the next 40 years underline the importance of research on this subject matter to 
find new possibilities for prevention. Preventing dementia will become a realistic possibility 
when non-genetic risk factors can be identified and targeted.  
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Figure 1 
Prevalence of dementia according to age in Germany (year 2004); Source: German Alzheimer Society (Deutsche 
Alzheimer Gesellschaft) 
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1.2 Different Forms of Dementia 
Dementia is the most common form of neurodegeneration and is a disorder characterized by 
impairment or loss of memory and at least one other cognitive domain (aphasia, apraxia, 
agnosia, or executive function). These must show a reduction of the previous level of function 
and be severe enough to interfere with daily function and independence (2). Progression of 
disease leads to significant personality changes, loss of both motor control and coordination, 
and an increasing inability to take care of oneself causing the patient’s loss of independence.  
The major dementia syndromes include: AD, VaD, dementia with Lewy bodies (DLB), 
Parkinson's disease with dementia (PDD), frontotemporal dementia (FTD) like Morbus Pick, 
and reversible dementias like Morbus Wilson. The most common forms of dementia are AD 
and VaD and will be discussed briefly. 
AD, the leading cause of dementia, is an incurable disease and is the classic example for 
cortical dementia. In contrast to subcortical dementias where the main problem is loss of 
functional motor skills, the main symptom in AD is the dementia itself. Upon autopsy a loss 
of cortex neurons is found especially in the temporo-basal (hippocampus) and temporoparietal 
region. The microscopic examination reveals necrosis of cells and deposition of senile plaques 
and Alzheimer fibrilles. An Amyloid angiopathy is frequently associated. AD can only be 
diagnosed by the presence of Amyloid plaques, NFT, synaptic and neuronal loss, and atrophy 
of the brain in certain cerebral regions by autopsy. Cerebral computed axial tomography 
(CAT) scan can show brain atrophy, but present studies show no clear correlation with 
clinical findings. A likely diagnosis can be made by the evaluation of cognitive tests like the 
Mini-Mental State Examination (MMSE) (40), in the living patient and by excluding other 
diseases such as stroke or hypothyroidism.  
VaD is the second most common form of dementia and is mainly caused by subcortical 
lacunary infarcts on the basis of cerebral microangiopathy (subcortical atherosclerotic 
encephalopathy) or less commonly caused by several cortical-subcortical infarcts on the base 
of macroangiopathy. These two forms are often combined. The localization and volume of the 
lesions are significant for the extent and progression of the demential syndrome. The entity of 
VaD is no longer understood as one distinct disorder but rather as a heterogeneous syndrome 
in which the underlying cause is some form of cerebrovascular disease like sequelae of 
recurrent strokes "multi-infarct dementia" and its ultimate manifestation is dementia. The 
three most important pathophysiological mechanisms are: large artery infarctions, usually 
cortical, sometimes also or exclusively subcortical in location; small artery infarctions or 
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lacunes, exclusively subcortical, in the distribution of small penetrating arteries, affecting the 
basal ganglia, caudate, thalamus, and internal capsule as well as the cerebellum and brain 
stem; and finally chronic subcortical ischemia occurring in the distribution of small arteries in 
the periventricular white matter. Neuroimaging should be performed in patients with 
suspected VaD, either cerebral CAT scan or the more accurate magnetic resonance imaging 
(MRI) scan. MRI will show cortical and subcortical infarctions as well as the presence of 
subcortical ischemic changes or leukoaraiosis. Diagnosis by radiographic finding is limited 
due to these white matter lesions (WML) being non-specific: it is impossible to differentiate 
between post-stroke patients with or without dementia.  
 
1.3 Risk Factors for Dementia 
The development of dementia is multifactorial, influenced both by genetic and environmental 
risk factors. Genetic factors seem to be involved in some cases as in mutations of the amyloid 
precursor protein (APP) and play a role mostly when referring to early-onset disease. Another 
strong genetic risk factor for AD is the presence of the epsilon 4 (e4) allele of the 
apolipoprotein E (apoE) gene (6). The vast majority of AD cases is late-onset and is probably 
influenced mainly by environmental factors. Besides age, around 20 non-genetic risk factors 
have been suggested for dementia. Unfortunately very few of them have been confirmed by 
randomized intervention trials. Elevated plasma tHcy and low-normal concentrations of B-
vitamins (folate, vitamin B12, and vitamin B6) have been postulated as risk factors for two 
most common causes of dementia Alzheimer’s disease (AD) and vascular dementia (VaD). 
Some of the environmental risk factors that are determined by lifestyle such as smoking 
increase not only the risk for dementia but increase plasma tHcy causing HHCY in turn a risk 
factor in itself for dementia. Intensified risk factor evaluation is important because other risk 
factors may be magnified in subjects with elevated plasma tHcy. The interpretation is that, 
even if raised total homocysteine turns out itself not causally related to dementia, it is a strong 
prognostic marker and subjects with HHCY should be intensely treated for conventional risk 
factors like hypertension. 
Table 1 shows the most important environmental, lifestyle factors and other diseases that 
modulate the risk for dementia.  
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Table 1. Environmental, lifestyle factors, and other diseases can increase the risk for dementia. 
Risk factor Key references cited are prospective studies 
Low blood pressure Qiu, 2005 (142) 
Hypertension Bunce, 2005 (14) 
Diabetes Biessels, 2006 (8) 
Cholesterol Shobab, 2005 (166) 
Obesity Whitmer, 2005 (203) 
Low intake of antioxidants Engelhart 2005 (35)  
Lack of fish in diet Morris, 2003 (122); Huang, 2005 (78) 
Low physical activity (midlife) Yoshitake, 1995 (208); Fratiglioni, 2004 (43); Rovio, 2005 (154); Larson, 2006 (101) 
Myocardial Infarction Luchsinger, 2005 (108) 
Atherosclerosis Honig, 2005 (77) 
Lack of alcohol consumption Mukamal, 2003 (128), Luchsinger, 2004 (109) 
Smoking Piyathilake, 2003 (141)  
Low testosterone in men Henderson, 2004 (66); Hogervorst, 2004 (76) 
Hormone replacement therapy  
in women over 65 
Craig, 2005 (25) 
Lack of NSAID use Szekely, 2004 (180) 
Increased blood markers  
of inflammation 
Engelhart, 2004 (34)  
Dietary copper intake Morris, 2006 (121) 
Lack of flavanoid-rich substances  
(tea, wine, chocolate) 
Nurk, 2009 (131) 
Lack of social or mental activities Karp, 2004 (90) 
Low education status Karp, 2004 (90) 
Depression Green, 2003 (56) 
HHCY and B-vitamin deficiency See table 2 and 3 
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1.4 Clinical Studies Validate Homocysteine’s Position as a Prognostic Marker for Cognitive 
Decline and Dementia 
HCY is a sulfur-containing and non-protein forming amino acid and occurs naturally in all 
humans. HCY acts as a cytotoxin and can be recycled into methionine or converted into 
cysteine with the aid of B-vitamins. Plasma tHcy is a nutritional metabolic marker. Mild to 
moderate HHCY (tHcy 12-30 µmol/l) is a marker for deficiencies in B-vitamins (folate, B12, 
B6).  
Neurodegenerative diseases include a wide group of disorders of various etiologies and 
clinical features. They all have in common structural and functional protein modifications, 
resulting in deterioration of certain nerve cells or neurons. Dementia, AD, and stroke are all 
examples of neurodegenerative diseases associated with HHCY. 
A causal link between HHCY and CNS disorders was first described in patients with 
cystathionine beta synthase (CBS) deficiency. These patients suffer from mental retardation, 
cerebral atrophy, seizures, and cognitive dysfunction in addition to severely elevated plasma 
concentrations of tHcy (>70µmol/l) (57;126). In a systematic review of nine case-control 
studies higher concentrations of tHcy and lower concentrations of folate and vitamin B12 in 
AD patients (193) were verified.  VaD is caused mainly by micro- and macrovascular lesions 
reflected by the presence of silent brain infarction and extensive white matter hyperintensity. 
The Northern Manhattan Study reported a concentration of HHCY >15µmol/l to be a strong 
independent risk factor for VaD and cerebral ischemia. (205). The Rotterdam Scan Study, in 
which 1077 healthy elderlies were examined, showed WML to be significantly associated 
with age and hypertension as well as with elevated tHcy (194). Another study showed HHCY 
in patients with VaD increased the danger for subcortical vascular encephalopathy even more 
than established risk factors like smoking, hyperlipidemia, and high blood pressure (206).  
The inverse relation between HHCY as well as in some cases folate deficiency and cognitive 
impairment and/or dementia have been shown in the following prospective studies and listed 
in Table 2 and 3. One of the first prospective studies was on patients with a clinical diagnosis 
of AD in a study by Clarke (23) where it was found that the baseline level of total 
homocysteine was related to the rate of disease progression. Several community-based 
prospective studies have since been completed in initially dementia-free subjects. When 
discussing epidemiological studies, it is important to consider which factors should be 
included as covariates. All studies should include gender, age and, in relation to the risk of 
dementia, additional risk factors such as the genetics (like presence of apoE4), years of 
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education, race, and possibly smoking, depression, and socioeconomic status should be 
considered. While some of these, notably age, gender, and smoking are also related to total 
homocysteine concentrations (149), there will be  a risk of over-adjusting if very strong 
determinants of total homocysteine, such as intake or blood concentrations of folate and 
vitamin B12, are included. Still, in the following prospective studies and listed in Table 2 one 
or more B-vitamins were included in the analysis, and the prospective association between 
tHcy and cognitive deficit remained significant and were able to validate this relationship. 
In a study with 32 healthy elderly individuals, age >65 years, by McCaddon et al. (112) 
concentrations of tHcy were able to predict cognitive decline showing a maximal effect on 
spatial copying skills tested by MMSE and Alzheimer's Disease Assessment Scale-cognitive 
subscale (Adas-Cog). Using Data from the Framingham study including 1092 dementia free 
subjects with a mean age of 76 years Seshadri et al. (165) demonstrated that after an 8 year 
follow-up an elevation of 5 µmol/l in plasma tHcy concentration increased the risk for AD by 
40 percent  (Figure 2). 
 
 
0
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(tHcy > 14 µmol/l)
All other subjects
Years of Follow-up
 
Figure 2 
Data from the Framingham Study on the increase in the incidence of dementia in elderly subjects with tHcy > 14 
µmol/l. The Framingham study is a follow-up study for 12 years that included 1092 subjects aged (68-97 years) 
without dementia at baseline. 
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Again, an inverse correlation between tHcy and attention and memory was demonstrated by 
Teunissen in 144 subjects over a follow-up of 6 years after adjusting for several factors, 
including folate (181). Even over a shorter follow-up of only 2.3 years Garcia et al. 
confirmed that tHcy was inversely correlated with executive function in 180 subjects. 
Increase in total homocysteine over time was associated with decline in test scores for 
executive function and learning. Analysis was adjusted for multiple factors, including folate 
and vitamin B12 (46). In a further study by Nurk et al., a higher risk for memory deficits after 
6 years was demonstrated in 2189 subjects, aged 65-67, when baseline concentration of tHcy 
was in the highest quintile and folate and vitamin B12 in the lowest quintile. Subjects with 
memory deficits at baseline showed higher tHcy and lower folate status (132). Another study 
with 819 subjects by Ravaglia et al. (146) calculated a hazard ratio for AD of 1.54 for each 
SD in tHcy showing a strongly dose-related effect.  The most recent study by Zylberstein et 
al. (212) examined mid-life HHCY and evaluated 1368 women 35 yrs later and is until now 
the only study with a follow-up longer than 8 yrs. This study showed that the highest tHcy 
tertile was related to a hazard ratio of 1.7 (95% CI 1.1-2.6) for developing any dementia, 2.1 
(95% CI 1.2-3.7, n=100) for AD and 2.4 (95% CI 1.3-4.7, n=68) for AD without 
cerebrovascular disease and confirmed midlife HHCY as a risk factor.  
 
Table 2. Prospective studies linking tHcy to cognitive decline or dementia 
Subjects Age Follow up Tests Results Study 
32 
healthy 
subjects 
(22 
female) 
> 65 yrs 5 yrs MMSE, 
ADAS-Cog 
tHcy predicted cognitive decline in 
healthy elderly, maximal effect on 
spatial copying skills 
McCaddon, 2001 
(112) 
 
 
1092 non-
demented 
subjects 
(667 
female) 
Mean 
76 yrs 
8 yrs Cases with 
dementia and 
Alzheimer 
disease were 
identified after 
8 years 
Relative risk 1.9 (1.3 to 2.8) for 
dementia and 1.9 (1.2 to 3.0) for AD. 
Increase in tHcy of 5 µmol/l increased 
the multivariable-adjusted risk of AD 
by 40 percent 
Seshadri, 2002 
(165) 
144 30-
80yrs 
6 yrs Tests of 
cognitive 
speed, 
attention, 
verbal 
memory 
Inverse correlation between tHcy and 
attention and memory. 
Adjusted for several factors, including 
folate 
Teunissen, 2003 
(181) 
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180 >65 yrs 2.3 yrs MMSE, verbal 
learning, 
dementia 
rating, 
executive 
function 
tHcy inversely correlated with 
executive function. Increase in tHcy 
over time associated with decline in 
test scores for executive function and 
learning. Multiple adjustments, 
including folate and vitamin 
B12 
Garcia, 2004 
(46) 
816 
 
 
 
74 yrs 3.8 yrs Incident 
dementia, 
including 
Alzheimer’s 
disease 
Hazard ratio for AD of 1.54 for each SD 
in tHcy. Strongly dose-related. Multiple 
adjustments, including cardiovascular 
disease, 
folate and vitamin B12 
Ravaglia, 2005 
(146) 
 
2189 
subjects  
65-67 
yrs 
6 yrs Memory 
performance 
(Kendrick 
Object 
Learning Test) 
Mean tHcy was higher and folate was 
lower in subjects with memory deficit 
at baseline. Baseline tHcy in the 
highest quintile, folate in the lowest 
quintile and vitamin B12 in the lowest 
quintile predicted a higher risk for 
memory deficit after 6  yrs. 
Nurk, 2005 
(132) 
1368 
women 
38-60 yrs 35 years MMSE, ADAS-
Cog, and 
Clinical 
Dementia 
Rating  
The highest tHcy tertile was related to a 
hazard ratio of 1.7 (95% CI 1.1-2.6) for 
developing any dementia, 2.1 (95% CI 
1.2-3.7, n=100) for AD and 2.4 (95% CI 
1.3-4.7, n=68) for AD without 
cerebrovascular disease. HHCY in 
midlife is an independent risk factor for 
the development of late-life Alzheimer 
dementia in women 
Zylberstein, 2009  
(212) 
 
 
 
The link between B-vitamin deficiency and cognitive dysfunction and/or dementia is more 
controversial. The following recent prospective studies on B-vitamins and subsequent 
impairment or dementia have shown striking findings and are listed in Table 3.  
Wang et al. (199) found that in subjects with a high baseline MMSE (≥ 26) and serum folate 
concentrations <12 nmol/L or serum vitamin B12 concentrations < 250 pmol/L, the relative 
risk of incident AD was increased versus those with normal concentrations of both vitamins. 
A study by Kado et al. demonstrated that after 7 years 370 elderly subjects aged 70-79 with 
folate in the bottom quartile (<3.15 ng/ml) had a 1.6-fold higher risk of being in the worst 
quartile for cognitive performance (86). The Veterans Affairs Normative Vitamin B Aging 
Study (185) found that the cognitive test that best related to B vitamin status and total 
homocysteine involved constructional praxis (a spatial copying task). The changes in scores 
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on this test over 3 years were strongly related to folate status even when tHcy and the other 
plasma B-vitamin concentrations were included in the regression. Corrada et al. (24) found 
that a higher intake than the recommended daily allowance of folate was associated with a 
significantly reduced risk of AD in 579 subjects when followed over 9.3 years, but no effect 
of vitamin B12 on risk reduction. In the prospective Conselice study with 816 subjects in an 
elderly community in Italy by Ravaglia et al. in 2005 (146) a strong dose-related inverse 
relationship was found between incident dementia and serum folate. Low serum folate (<11.8 
nmol/l) at baseline was associated with 2-fold risk of AD after adjustment for tHcy. No 
association was found with vitamin B12 concentrations. Nurk et al. tested episodic memory 
scores in 2173 subjects over a follow-up of 6 years (132) and discovered that baseline serum 
folate was dose-related to test score; a decrease in folate over 6 yr associated with lower test 
score. No prospective association with vitamin B12 was found. Another study in 2006 by 
Ravaglia et al. (145) including 165 subjects with MCI a hazard ratio for conversion to AD 
was 3.11 for those with low folate (<10.4 nmol/l) was found. 
When trying to summarize the results on B-vitamins we encounter inconsistent findings. On 
the one hand, several vitamin B12 prospective studies were able to show an inverse 
relationship with cognitive decline or the incidence of dementia like the study by Wang et al. 
(199), on the other hand there are a number of studies finding no association with vitamin B12 
when adjusting for other B-vitamins and tHcy (24;86;185) We must keep in mind though that 
this may be a result of different populations studied, different tests, assays, and endpoints. A 
further factor may be that concentrations of serum vitamin B12 don’t automatically reveal the 
amount of vitamin B12 available for cellular function which is carried by transport protein 
transcobolamin-II. Better functional markers might be tHcy, although not specific for vitamin 
B12 status, methylmalonic acid and/or holotranscobolamin-II (67;105;157). 
We can conclude that in several very different population studies, low-normal blood folate 
concentrations were associated with a risk of developing dementia 
(24;86;132;145;146;185;199) However some studies that need to be considered were not able 
to confirm these results, on the contrary one reported that higher blood concentrations of 
folate were associated with a greater rate of global cognitive decline, even though in the same 
cohort a strong positive cross-sectional relationship was found between folate and cognition 
(120). These conflicting findings need to be examined further and the possibly harmful effect 
of high folate supplementation (183) must be taken into consideration especially in the 
context of low vitamin B12 status (123). 
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Table 3. Prospective studies linking B-vitamins (low folate status) and subsequent cognitive impairment or 
dementia 
Subjects Age Follow 
up 
Tests Results Study 
370 >75 yrs 3 yrs Incident 
dementia 
and AD 
Low folate (< 10 nM) alone, or low folate and low 
vitamin B12 (< 150 pmol/l) were associated with 
incident AD, adjusted for age, gender, education. 
Only significant in subjects with baseline MMSE > 
26 
Wang, 2001 
(199) 
370 74 yrs 7 yrs Multiple 
cognitive 
domains: scores 
summed 
Baseline folate and vitamin B6 inversely related to 
cognitive decline when adjusted for age and 
gender, but only folate significant 
when other covariates including tHcy were added 
Kado, 2005 
(86) 
321 men  3 yrs MMSE, working 
memory, verbal 
memory, verbal 
fluency, 
constructional 
praxis 
Baseline plasma concentrations and dietary intake 
of folate, vitamin B6, and vitamin B12 related to 
praxis; baseline dietary folate related to verbal 
fluency. Change in praxis scores over 3 yrs was 
dose-related to folate and vitamin B6 
concentrations and intake. Multiple adjustments, 
including education. Folate remained associated 
when all 3 vitamins and tHcy were included. 
Tucker, 2005 
(185)  
579 70 yrs 9,3 yrs Incidence of 
possible 
or probable 
AD 
Higher intake (> RDA) of folate (RR 0.4) or 
vitamin B6 (RR 0.4) associated with reduced risk of 
AD. No effect of vitamin B12. Multiple 
adjustments. When folate and vitamin B6 included 
together, only folate remained significant 
Corrada, 2005 
(24) 
816 74 yrs 3.8 yrs Incident 
dementia, 
including 
Alzheimer’s 
disease 
Low serum folate (<11.8 nmol/l) at baseline 
associated with 2-fold risk of AD after adjustment 
for tHcy and many covariates, including 
cardiovascular disease, ApoE4. Dose-related 
inverse relationship of folate with cumulative 
incidence. No association with vitamin B12 
concentrations 
Ravaglia, 2005 
(146) 
2,173 65–67 
yrs 
6 yrs Episodic 
Memory 
scores 
Baseline serum folate dose-related to test score; 
increase (decrease) in folate over 6 yr associated 
with higher (lower) test score. No prospective 
association with vitamin B12. Multiple adjustments. 
Nurk, 2005 
(132) 
165 with 
MCI 
 2,8 yrs Conversion to 
AD 
Hazard ratio for conversion to AD was 3.11 for 
those with low folate (<10.4 nmol/l). Multiple 
adjustments. 
Ravaglia, 2006 
(145)  
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The following examples of retrospective studies further verify the link between HHCY and 
cognitive decline and are listed below in Table 4 for further review.  
Elevated plasma tHcy (>13 µmol/l) in 200 healthy postmenopausal women, aged 56-67, was 
shown to be linked to poor performance of combined verbal and working memory 
independent of age and hormone therapy (21). It has also been demonstrated in 209 subjects 
with a mean age of 76 that both tHcy and methylmalonic acid (MMA) were independently 
and inversely correlated with movement and cognitive performance (102). In stroke free 
subjects MMSE scores were negatively correlated to tHcy in subjects >65 years, and a 
concentration of tHcy >15 µmol/l was associated with 3.3 less points on MMSE test (205). 
Concentration of tHcy correlated negatively to cognitive performance in 812 dementia and 
stroke free subjects after adjusting for possible confounding factors (32). In the Framingham 
Offspring Study with 2096 dementia and stroke free subjects aged >40 years, concentrations 
of tHcy were inversely related to 9 of 12 cognitive measures tested and was significant in 
subject 60 years or older (33). These results were confirmed by other studies on elderly 
people (117;147;163). Serum concentrations of markers of vitamin B12 deficiency were also 
related to certain cognitive functions (72;114). Also in healthy individuals, B-vitamin plasma 
concentrations seemed to be inversely related to deficits in neuro-cognitive tests (54).  
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Table 4. Examples for retrospective studies linking tHcy to cognitive decline or dementia 
Subjects Age  tHcy, vitamins Tests Results Study 
200 healthy 
women 
56-
67 
yrs 
Mean 
 tHcy= 10 µmol/l 
California Verbal 
Learning Test-II, 
Ten unrelated words, 
WAIS Letter-
Number Sequencing 
tHcy > 13 µmol/l was associated 
with poor performance of combined 
verbal and working memory 
independent of age, and hormone 
therapy 
Clark 
(21) 
209 subjects 76 
yrs  
Means 
 tHcy= 17.2 µmol/l 
MMA= 220 nmol/l 
Folate= 16.0 nmol/l 
B12= 325 pmol/l 
Postural-Locomotor-
Manual test 
A battery of 
cognitive tests 
 tHcy and MMA correlated 
independently with movement and 
cognitive performance 
Lewerin 
(102) 
2871 
subjects free 
of stroke  
40 
yrs  
Means 
 tHcy= 10.2 µmol/l  
 MMA= 214 nmol/l 
17% had  
MMA > 271 nmol/l 
MMSE scores MMSE scores were negatively 
related to tHcy in subjects > 65 yrs. 
3.3 lower MMSE points in subjects 
with tHcy > 15 µM 
Wright 
(205) 
812 subjects 
free of 
dementia 
and stroke 
 Means 
tHcy= 10.0 µmol/l 
Folate= 38.5 nmol/l 
B12= 389 pmol/l 
Visual spatial 
organization, 
working memory, 
scanning tracking, 
abstract reasoning 
tHcy was negatively related, and 
vitamin B6 was positively related to 
cognitive performance even after 
adjusting for possible confounding 
factors   
Elias 
(32) 
2096 
subjects free 
of dementia 
and stroke 
> 40 
yrs 
Mean 
 tHcy= 10.32 µmol/l 
in 705 subjects aged 
60-82 years 
Multiple measures 
of cognitive function 
tHcy was inversely related to 9 of 
12 cognitive measures tested. This 
was significant in subjects who 
were 60 years or older    
Elias 
(33) 
1789 
elderly, 
 60 
yrs  
Median 
 tHcy= 9.8 µmol/l 
The modified 
MMSE test, and 6 
other cognitive tests 
A modest, significant correlation 
was observed between tHcy and 
several measures of cognitive 
function  
Miller  
(117)  
650 healthy, 
free of 
dementia 
 65 
yrs 
Mean tHcy was 
higher in subjects 
with lower MMSE 
scores (11.9 vs. 14.5 
µmol/l for scores > 
28 vs. < 26 
MMSE test tHcy is an in depended and graded 
risk factor for cognitive decline 
with age 
Ravaglia  
(147) 
 
When interpreting the studies described above, no matter how statistically accurate they have 
been conducted, they are observational and not able to differentiate causality from reverse 
causality. Elevated concentration of tHcy can be lowered by supplementing B-vitamins. To 
show causality between B-vitamins, or tHcy and dementia it is necessary to carry out 
randomized clinical trials with doses of B vitamins that lower tHcy in the elderly. Several 
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studies have tested the hypothesis that lowering tHcy might improve cognitive function and/or 
decrease the rate of cerebral atrophy. Some studies were able to confirm this (13;30;132;195) 
others were not (103). One study on elderly adults with vascular disease supplemented with 
2.5 mg folic acid and 0.5 mg vitamin B12 for the duration of a year showed no improvement 
of cognitive function even though tHcy was significantly decreased (178). In a further study 
including elderly patients with vitamin B12 deficiency who were treated with folic acid and 
vitamin B12 during a time frame of 24 weeks failed to show positive results, as well (36).  
Taken together, the associations between HHCY and cognitive dysfunction have been 
validated. HHCY position as a prognostic marker for cognitive decline and dementia has been 
demonstrated. Elevated concentrations of tHcy can be lowered by supplementing B-vitamins. 
Yet, their effect on cognitive function in vitamin intervention studies remains inconclusive. 
Because dementia is developed over several decades, vitamin treatment for a short duration 
might not be sufficient and will have to be initiated early in the disease process and last for 
several years in order to show an effect on cognitive decline in order to prove causality. 
 
1.5 Pathobiochemical Mechanisms in Dementia 
Upon autopsy and radiographic examinations the major dementia syndromes each manifest 
differently. A multifactorial pathogenesis seems likely when considering the number of risk 
factors associated with the development of dementia. Deposition of Amyloid beta (Aβ) in the 
brain and phosphorylation of tau leading to accumulation of NFT in neuronal cell bodies are 
associated with AD. Influencing functional proteins that enhance these processes seem to be 
an important link between risk factors and neurodegeneration.  
 
Amyloid beta hypothesis 
Aβ is a peptide of 39–43 amino acids that appears to be the main constituent of amyloid 
plaques in the brains of AD patients. As part of the normal aging process Aβ is deposited 
extensively in the brain. One of the characteristics in patients with AD is the widespread 
deposition of Aβ within senile plaques and in cerebral and meningeal blood vessels (52;111). 
The endoplasmatic reticulum protein (Herp) has recently received attention because of its 
capacity to enhance the γ-secretase activity and thereby the Aβ 1-40 accumulation in the brain 
(156). There is a relation to cognitive decline and low concentrations of Aβ in cerebrospinal 
fluid (CSF) samples from AD patients and VaD (41).  
 
- 24 - 
 
Tau hypothesis 
Tau is an important protein in the human brain implicated in memory decline and dementia. It 
is an intracellular microtubule-associated protein, stabilizing and promoting the 
polymerization of microtubules (202). Microtubules play an important role in the protection 
of cellular architecture of neurons. Normally tau is found in the axons of neurons (9). In AD 
tau becomes hyperphosphorylated and aggregates into PHF which accumulate in neuronal cell 
bodies as NFT. These correlate with cognitive deficits, neurodegenerative disorder and 
dementia. NFT (1;96) cause neuron degeneration and neuron loss in the hippocampus, 
substantia innominata, locus coeruleus, and in the temporal, parietal, and frontal cortex. 
Making tau detached and accessible for proteolysis is probably key in neuroprotection. The 
enzyme protein phosphatase 2A (PP2A) can dephosphorylate P-tau in PHF (201). Activation 
of kinases with the capacities of phosphorylating tau (GSK3beta, phosphatidylinositol 3-
kinase (PI3K), MAP kinase) may be stimulated by increased Aβ (37). Increased P-tau may be 
related to lower phosphatase activity or to an increased kinase activity. Some studies were 
able to show a decreased expression or activity of PP2A in cerebral tissue of patients with AD 
(196) (169). In fibroblasts of patients with AD, the expression of PP2A protein was reduced; 
simultaneously mRNA for PP2A was increased. This suggests the defect or failure lies not in 
the pretranslational pathway but possibly in posttranslational modifications or in the protein 
stability itself (210). A therapeutic potential for AD may involve influencing these 
phosphatases or kinases. 
 
Mixed dementia (AD with cerebrovascular disease) refers to the concurrence of AD and VaD 
and is increasingly recognized as a condition requiring independent consideration. It is often 
difficult to distinguish AD from VaD, let alone to determine which is etiologically most 
important when both are present. The high prevalence of both AD and VaD is such that their 
concurrence is common. Whether these vascular lesions are coincidental or causal in the 
pathogenic processes of AD remains to be defined. In autopsy series, vascular pathology was 
found in 34 to 50 percent of those with pathologic AD. About one third of the patients 
diagnosed with VaD had AD pathology at autopsy (88). In addition to their frequent 
coincidence, there is increasing evidence that AD and VaD may share etiologic or pathogenic 
features and/or influence each other's course. 
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2 Homocysteine 
 
2.1 Overview 
HCY is a cytotoxin which is why this product should be eliminated from the cell or converted 
to less harmful substances. A relationship between HHCY and pathologic alteration in the 
human organism was first described in 1962. Carson and Neil reported elevated HCY 
concentrations in the urine of mentally retarded children in Belfast (17). This disease was 
named homocystinuria and was discovered by two other groups simultaneously in 
Philadelphia and Milwaukee (49;173). Pathological examination showed distinct vascular 
lesions, thrombosis and fatty degeneration of the liver (51). Biochemical analysis showed that 
a deficiency of vitamin B6-dependant enzyme CBS forms the basis of homocystinuria (125). 
Today over 100 different mutations have been identified in the gene encoding this enzyme 
(97). Homocystinuria is a rare genetic disease associated with a severe HHCY (plasma tHcy 
100-250 µmol/l). Mild to moderate HHCY (plasma tHcy 12-30 µmol/l) is common in elderly 
people (69;84;93;176). The cause is often a folate, vitamin B12, and/or vitamin B6 deficiency 
(22;45;55;69;93;176), as well as a decline of renal function with increased age (70;130;190). 
Moderate HHCY in the adult is a risk factor for atherosclerotic (68;176;198), thrombotic (92), 
pregnancy complications (115), and neurodegenerative diseases (47;143). 
Concentrations of tHcy between 10-12 µmol/l are considered normal. HHCY is either mild 
when tHcy is between 16-30 µmol/l, moderate when tHcy is between 31-100 µmol/l, or 
severe when tHcy > 100 µmol/l (81). Chemical structures of homocysteine, methionine, and 
cystathionine are shown in Figure 3. 
 
Homocysteine HS-CH2-CH2-CH(NH2)-COOH 
Methionine CH3-S-CH2-CH2-CH(NH2)-COOH 
Cystathionine HOOC-CH(NH2)CH-S-CH2-CH2-CH(NH2)-COOH 
 
Figure 3 
Chemical structures of homocysteine, methionine, and cystathionine 
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2.2 Biochemical Aspects of Homocysteine 
HCY is a sulfur-containing, non-protein forming amino acid and a product in the metabolism 
of the essential amino acid methionine (118). Methionine enters the body by alimentary 
animal proteins. HCY is a small molecule (molecular weight: 135 Dalton) and not well 
soluble in H2O. The sulfur containing amino acid methionine enters the human organism 
exclusively via alimentary proteins. It functions as a universal methyl group donor in the 
human body when activated to S-adenosyl methionine (SAM) by the methionine 
adenosyltransferase (Figure 4). These methyl groups are transferred to a wide spectrum of 
acceptors, such as melatonin, DNA, RNA, protein, epinephrine, myelin, creatine, and 
phospholipids. When one of these acceptors is methylated, S-adenosyl homocysteine (SAH) is 
formed out of SAM by S-adenosylmethionine-dependent methyltransferase. SAH in turn can 
then be hydrolyzed to form HCY in a reversible reaction mediated by SAH-hydrolase.  
Because HCY is toxic, a low cellular HCY concentration is necessary. The cell has three 
possibilities to achieve this: elimination from the cell, remethylation to methionine, or the 
irreversible degradation via the transsulfuration pathway (Figure 4). HCY can be 
remethylated to form methionine by accepting the methyl group of 5-methyltetrahydrofolate 
(5-MTHF) by the vitamin B12-dependant enzyme methionine synthase (MS). Alternatively 
this can be achieved by receiving the methyl group from betaine by the betaine homocysteine 
methyltransferase (BHMT). However this reaction is primarily limited to the liver and 
consequently plays a secondary role as determinant of tHcy concentrations. 
If there is an excess of methionine, like after a protein rich meal, HCY flows preferably via 
the transsulfuration pathway. HCY and serine are condensed to form cystathionine (Cys) by 
CBS and then to cysteine by γ-cystathionase (CS) and then to glutathione, both enzymes 
being irreversible and requiring vitamin B6 as a cofactor. Folate, vitamin B12, and vitamin B6 
are essential in maintaining a constantly low tHcy concentration. Because these B-vitamins 
are important cofactors for HCY catabolism, an elevated concentration of tHcy can indicate 
B-vitamin deficiency (39;167). 
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Figure 4 
Homocysteine metabolism, pathways, and enzymes: a: methionine synthase (MS) and betaine homocysteine methyltransferase (BHMT), b: SAM-dependent methyltransferase, c: 
SAH-hydrolase, d: cystathionine beta synthase (CBS), e: γ-cystathionase
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Besides being important cofactors for enzymes in HCY metabolism, these vitamins have 
further independent characteristics (7;20;152;197). Folate deficiency not only induces HHCY, 
but is also responsible for hypomethylation, DNA damage, and disturbed cellular proliferation 
(94;175). Vitamin B12 is a cofactor for MS and is hereby linked with folate utilization. 
Therefore an isolated vitamin B12 deficiency, in spite of a sufficient folate supply, can reduce 
HCY-remethylation and hereby cause hypomethylation. Thereby HCY is increased, and folate 
becomes functionally deficient, despite its normal concentration in plasma. Deficiencies in 
folate, vitamin B12, and vitamin B6 limit enzyme activity, thereby blocking degradation of 
HCY and consecutively cause an intracellular increase of HCY concentration (29;83).  
HCY can be actively transported out of the cell and into the plasma where less than 2% can be 
found in its free and reduced form. Only 0.29% of HCY are found in the form of HCY-
Thiolacton which is significant because of its high toxicity. HCY is mainly bound to proteins 
in two different variations. The first binds via SH-group and the second via amino group 
(148). The N-protein bound HCY is associated with functional damage of proteins and cannot 
be detected by current assays (82). The main component though is made up of disulfide 
complexes where HCY is bound by SH-groups of plasma proteins, like albumin. Mixed 
disulfides are formed also with cysteine, as well as symmetric disulfides with HCY producing 
homocystine (187). Free reduced HCY is not very stable and not soluble at neutral pH levels 
(60). Therefore the concentration of free HCY is extremely low (only 1-2% of concentration 
of tHcy in the physiological range of < 12µmol/l) (150). When HCY is reduced, it can be 
dissolved out of its disulfide form. This is usually used in many in vitro assays designed for 
quantification of tHcy concentrations in plasma. Table 5 shows the distribution of main forms 
of HCY in vivo in percent. 
 
Table 5. Different components of plasma HCY 
Reduced form:  
Free Homocysteine (HCY) 1-2% 
Oxidized form:  
Homo-Disulfide; Homocystine 5-10% 
Mixed Disulfides:  
Protein-bound Homocysteine 80-90% 
Cysteine-Homocysteine 5-10% 
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Approximately 70% of HCY is metabolized in the epithelia of the kidneys. Only small 
amounts of HCY are generally detected in the urine of healthy individuals. When kidney 
function is reduced, lower levels of remethylation and transsulfuration are found, thereby 
leading to accumulation of HCY and consecutive HHCY (190-192). This may also explain 
why especially older patients with reduction of renal function often have HHCY.  
 
2.3 Homocysteine Metabolism in the Central Nervous System 
The HCY metabolism described above gives a general overview but probably does not occur 
in full except in a few tissues like the liver or kidney (39). In the brain the metabolism is 
limited (16). BHMT has not been detected in brain tissue. In the liver about 50% of cysteine 
for glutationine synthesis is produced by the transsulfuration pathway. However this is not the 
case in the brain. CBS expression and activity is observed in the brain, but limited brain 
cystathionase activity is detected in only a few studies with wide regional span leading to the 
conclusion that expression and function of cystathionase in the brain seems questionable. 
The metabolism of HCY is an important source of SAM (162). This methyl donor is 
important for the synthesis and catabolism of neurotransmitters, phospholipids 
(phosphatidylcholine being the methylated product of phosphatidylethanolamine), DNA 
methylation, and activation of several essential enzymes in the brain. The role of SAM in the 
brain corresponds with SAM reducing apoptosis by 50% caused by HCY in cortical neuronal 
cells (75). SAM supplementation after ischemia was able to improve the blood brain barrier 
and neuronal survival (144). 
A specific cellular receptor seems to be responsible for the transport of HCY in brain cells 
(58). Transfer between different brain regions and between brain and blood has not yet been 
well studied. The integrity of the blood brain barrier seems to play an important role in the 
distribution of HCY. Severe HHCY in patients with CBS deficiency is associated with a 10-
fold increase in CSF tHcy (179). Even though HCY remethylation doesn’t occur with the aid 
of betaine in the brain, lowering the concentration of plasma tHcy with betaine causes a 
significant decrease of CSF tHcy (179) suggesting HCY can be transported across the blood 
brain barrier in both directions. Several neurological diseases are associated with increased 
brain and CSF concentrations of tHcy or increased concentrations of its precursor SAH 
(80;151). In general, plasma tHcy concentrations are 20- to 100-fold higher than CSF 
concentrations and plasma tHcy is positively correlated to brain or CSF concentrations (135). 
Therefore an increased plasma tHcy concentration may reflect an increased brain or CSF tHcy 
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concentration. HHCY leads to increased SAH, a potent competitive inhibitor of many SAM-
dependent methyltransferases in the human brain. Hypomethylation in the brain is related to 
numerous functional and biochemical defects. The importance of methylation for the CNS has 
been demonstrated. Accordingly, supplementing SAM after ischemia improves the blood 
brain barrier and neuronal survival and protects against disturbances in brain phospholipids 
(87;184). Other limiting factors for HCY metabolism in the brain are that folate must be 
reduced before entering the blood-brain barrier, and the majority of brain cysteine and vitamin 
B12 must be imported from the blood. 
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3 Factors leading to Hyperhomocysteinemia 
 
3.1 Genetics in Hyperhomocysteinemia 
It is important to differentiate between the autosomal recessive form of severe HHCY and the 
mild HHCY which is induced by heterozygote form, and minor defects of the CBS, 5,10- 
methylenetetrahydrofolate reductase (MTHFR), or MS. The severe form of HHCY develops 
because of an autosomal recessive genetic deficiency in CBS or MTHFR. The incidence for 
homozygosity in CBS deficiency is documented as 1:200.000-1:344.000. Heterozygote’s 
plasma tHcy is increased by 2- to 4-fold in comparison with healthy individuals. While a 
deficiency of CBS can be treated by high dose vitamin B6 in combination with folic acid, so 
far no therapeutic options exist for MTHFR deficiency, explaining why its prognosis is far 
worse (127). The MTHFR can also be affected by different point mutations, in which a partial 
activity of the enzyme is preserved. The most important factor for the development of mild 
HHCY is the thermolabile variant of MTHFR. It results from the point mutation (C677T) in 
the encoding region for the binding place of the MTHF in the MTHFR molecule. The amino 
acid alanine is replaced by valine. The consequence of this mutation is the reduced specific 
activity and catalytic function at 37°C of the TT-enzyme in comparison with the CC-
genotype. Prevalence for homozygosity of this MTHFR gene mutation is between 5-18%, 
depending on population and race (12;119). A mild form of HHCY is only acquired when 
folate is deficient or low. When folate has an increased but still normal or elevated 
concentration, HHCY does not develop, because the high folate concentrations stabilize the 
TT enzyme (63). 
 
3.2 Hyperhomocysteinemia and Vitamin Deficiency 
Deficiencies in vitamins functioning as co-enzymes in HCY metabolism like folate, vitamin 
B6, or vitamin B12 can induce HHCY. A substitution can normalize their plasma 
concentrations  (11;89;174). 
 
3.3 Diseases Associated with Hyperhomocysteinemia 
Disease like renal failure, hypothyroidism, pernicious anemia and several malignant tumors 
are associated with elevated tHcy concentrations (62;104;153). 
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3.4 Influence of Medication and Lifestyle on Total Plasma Homocysteine 
There are a large number of substances influencing tHcy. Some are direct antagonists of 
cofactors and enzyme activity; others have indirect effects i.e. by inducing malabsorption in 
the gastrointestinal tract or enzyme induction. Table 6 and Table 7 show the influence on 
plasma tHcy caused by different medications and lifestyle factors.  
 
Table 6. Influence of medication on total plasma homocysteine 
Medication ↑↓ Mechanism Reference 
Theophylline ↑ Vitamin B6 antagonist (186) 
Nitrousoxide ↑ Inactivation of MS (26) 
Methotrexate ↑ Competitive inhibition of folate (61) 
Fibrate ↑ Peroxisome proliferator-activated receptor (PPAR) (85) 
Niacin ↑ Vitamin B6 antagonist (48) 
L-DOPA ↑ Substrate for SAM-dependant methylation (211) 
Antiepileptics ↑ Decrease of folate and vitamin B6 (4) 
N-acetylcysteine ↓ Cleavage of disulfide bridges (161) 
Proton pump inhibitors ↑ Increase of stomach pH, causes vitamin B12 deficiency (159) 
Estrogen, progesterone ↓ Hormone function (116) 
Tamoxifen ↓ Partial agonist of estrogen receptor (18) 
Metformin ↑ Inhibition of intrinsic factor secretion (15) 
 
 
Table 7. Influence of lifestyle factors on plama homocysteine 
Lifestyle ↑↓ Mechanism Reference 
Smoking ↑ Interference with cobalamin, pyridoxine, and folate; production of radicals (15) 
Alcoholism ↑ General malnutrition, block of methylation reaction (160;182) 
Coffee consumption 
 
↑ Vitamin B6 antagonism (59) 
Vegetarian Diet ↑ Vitamin B12 deficiency (71) 
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4 Pathomechanisms linking Homocysteine to Neurodegeneration 
 
There are several mechanisms by which HHCY can damage the brain. Elevated 
concentrations of plasma tHcy therefore either have a direct neurotoxic effect or cause 
damage by disturbing the methylation potential (SAM/SAH) of the brain.  
HHCY can cause lowered SAM and elevated SAH, the potent competitive inhibitor for 
methyltransferases. Increased concentration of tHcy is associated with increased production of 
SAH via the reversible reaction mediated by SAH-hydrolase. The importance of the 
transmethylation pathway in the brain can be recognized from studying patients with SAH-
hydrolase deficiency. This rare disorder was associated with a diffuse white matter atrophy, 
restricted myelination of some brain regions, abnormal spectroscopy of cerebral white matter, 
and developmental delay. The neurological symptoms and brain abnormalities in the 
described patients were probably attributed to the severe SAH elevation (>100-fold). In 
contrast, plasma tHcy was only slightly elevated (14.5-15.9 µmol/l) (5). Methyl groups are 
required for synthesis and catabolism of neurotransmitters as well as maintaining DNA 
methylation and hence are important in maintaining neurological health. A lowered ratio in 
SAM/SAH causes DNA damage and apoptosis demonstrating one important mechanism of 
neurotoxicity (98). 
Experimental HHCY leads to increased concentrations of tHcy and SAH in rat brain (50). 
Neurological damage has been reported in CBS enzyme deficient mice (CBS -/+ or CBS -/-), 
where tHcy increased by approximately 2- to 50-fold in comparison to wild type mice, 
depending on the genotype and the type of diet. These animals show alterations in neuronal 
plasticity, suffered from severe retardation, and died early. Animals exposed to HCY 
accumulate this compound in the brain, suffer from restricted growth, neural or cognitive 
dysfunction, and impaired brain energy metabolism.  
 
4.1 Homocysteine and Hypomethylation 
Hypomethylation is one important mechanism explaining the toxic effect of elevated tHcy. 
Metabolic markers of methylation in blood like SAM and SAH reflect tissue methylation.  
(94;175). HCY increases neuronal death and DNA damage (98). PS1 gene expression is one 
important example that has been tested in relation to DNA methylation  (44;158;164). 
Presenilins are a family of transmembrane proteins that function as a part of the γ-secretase 
protease complex. PS1 mediates the formation of Aβ from APP. When DNA is 
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hypomethylated, APP processing and hence Aβ production is accelerated by an up-regulation 
of PS1 gene. Interestingly, Aβ production can be reduced by silencing of the PS1 gene by 
exogenous SAM. These results suggest a silencing of the PS1 gene may be a target therapy 
for AD patients (158;164) and that the treatment of folate and vitamin B12 deficiency might 
protect against Aβ accumulation in dementia by supplying methyl groups.  
Factors that lower phosphorylation or enhance dephosphorylation of certain proteins may 
offer an approach to prevent some forms of neurodegeneration like in AD. Under 
physiological conditions, tau phosphorylation is regulated by a dynamic equilibrium between 
the kinases and phosphatases acting on the molecule. An important biological reaction where 
hypomethylation may increase damage to the brain in AD is the formation and clearance of P-
tau (Figure 5). The dephosphorylation of P-tau is accomplished by the enzyme protein 
phosphatase 2A (PP2A). PP2A is regulated by the enzyme protein phosphatase 2A 
methyltransferase (PPMT) which is SAM-dependent. PP2A is composed of three subunits A, 
B and C. The regulatory subunit B is involved in substrate recognition. Methylation of the 
subunit C at Leu-309 by means of a specific SAM-dependent methyltransferase (PPMT) 
facilitated assembly of the AC-dimer subunit and forming the PP2A holoenzyme. This means 
reduced methylation capacity can increase P-tau by decreasing dephosphorylation. 
Dephosphorylation is important because it enables the detachment of tau, making proteolysis 
accessible. In the brain tissue of AD patients expression or activity of PP2A was reduced 
compared to controls (169;196). Furthermore fibroblasts of AD patients showed a low 
expression of PP2A (210).  
Clinical studies have not yet tested the effect of methylation on the pathophysiology of tau or 
Aβ. 
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Another mechanism which may accelerate P-tau accumulation is the increase of Aβ by the 
activation of the kinases that phosphorylate tau (GSK3beta, phosphatidylinositol 3-kinase 
(PI3K), MAP kinase) (37). 
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Figure 5 
SAM, SAH, and HCY influence the dephosphorylation of P-tau and Aβ metabolism. 
 
There seems to be a positive association between plasma concentrations of tHcy and that of 
Aβ 1-40 (79). The endoplasmatic reticulum protein (Herp) is responsive to HCY and is 
capable of enhancing the γ-secretase activity and thereby the Aβ 1-40 accumulation in the 
brain (156). Along with this direct mechanism there is evidence that HCY can act neurotoxic 
by potentiating Aβ neurotoxicity (74;99). Neuronal cells are susceptible to not only 
intracellular but also extracellular accumulation of Aβ 42 induced by homocysteic acid (64). 
HCY also increased Aβ toxicity and caspase-3 activation in vascular smooth muscle cells 
dose-dependently. When taking into account the current data published on this subject matter, 
HCY seems to accelerate dementia by stimulating Aβ deposition in the brain. 
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4.2 Homocysteine and Glutamate Receptors 
HCY is capable of acting on N-methyl-D-aspartate receptor subtype as a glutamate receptor 
agonist. Brain cells produce homocysteic acid from HCY oxidation which is then released 
when stimulated. Homocysteic acid can function as an excitatory neurotransmitter through the 
activation of the NMDA receptor. Hence the neurotoxicity can be blocked by NMDA receptor 
antagonists (106). 
 
4.3 Homocysteine and Inflammation 
There are few studies examining HHCY’s effect on inflammation. Some studies were able to 
show that a negative association between higher HCY and cognitive function was strongest in 
persons with a high level of IL-6 (207), CRP, and Alpha-1-antichymotrypsin (ACT) (189). 
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5 Aim of Work and Study Hypothesis 
Although there is clear evidence that there is an association between HHCY and 
neurodegenerative disease, the causal link between the two is still not well studied.  Of the 
wide range of risk factors that have been postulated, HHCY is one of the few that could easily 
be influenced. HHCY is a marker for vitamin deficiency and is the main reason for 
hypomethylation.  The aim of our work was to contribute further to risk factor evaluation by 
identifying neurodegenerative changes in the presence of HHCY and B-vitamin depletion and 
to further improve pathobiochemical understanding by clarifying the influence HHCY has on 
phosphorylation and methylation.  
The causal effects of HCY metabolism on neurodegeneration in vivo remain elusive. 
Therefore we tested the hypothesis that increased tHcy is causally related to accumulation of 
P-tau protein in brain tissues via affecting PP2A activity or level. For this purpose, we studied 
Wistar rats fed methionine or homocystine rich diets, compared to those fed a control diet. In 
addition we proposed that changes in phosphorylation caused by HHCY can lower the activity 
of PP2A and thereby causing enhanced tau phosphorylation and decreased dephosphorylation 
of other functional proteins like PNF-H in rat brain. We also studied a marker for 
inflammation, tumor necrosis factor alpha (TNF-), in brain tissue extracts in relation to the 
metabolic conditions caused by the diets. Hopefully, this study can promote impulses for 
future strategies for large-scale multi-centered randomized clinical trial studies with HCY-
lowering vitamins like folate to establish if a proportion of dementia in the world can be 
prevented. 
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IV Materials and Methods  
 
1 Study Design 
We induced HHCY in Wistar rats by two different approaches and tested the effect on blood 
and brain methylation, neurodegenerative markers, and functional protein activity. Our study 
consisted of a feeding experiment with three different treatment groups. Nineteen animals 
received a homocystine enriched diet (1.7%), 18 received a methionine rich diet (2.4%), and 
18 received a control diet. The rats’ age at recruitment was 8 weeks and the duration of the 
study was 5 months. Body weight was determined before and at the end of the experiment. 
After the end of the 5 months, animals were euthanized. The brain was removed for further 
analysis. 
 
2 Animal Model 
 
Photo 1 
A female Wistar rat, 7 months old at the end of the dietary intervention 
 
We used 8 week old female Wistar rats purchased from Charles River (Sulzfeld, Germany) 
with similar starting body weight of approximately 200g. To ensure an acclimatization of the 
animals after their arrival, they were fed several days with a standard diet and tap water. 
Subsequently the animals were randomized into three treatment groups. For randomization 25 
animals were put into a large cage. From the middle of the cage, a rat was removed and 
assigned to one of the groups. In the first cycle rats were sorted into groups 1-3; the second 
cycle was distributed in reverse order, continuing until the cage was empty. The remaining 
animals were randomized by the same procedure ensuring group equality. 
All rats were marked with specific ear hole combinations composed of complete and semi-
complete holes, and their tails were marked with red and black color combinations. In 
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addition, every cage was labeled with a specific symbol assigned to a certain animal diet 
group, and the food was colored according to the diet, allowing a definite identification and an 
accurate administration of the pellets. Animals were placed in an air-conditioned room where 
an automatic timer simulated a 12 hour to 12 hour day and night cycle. Humidity and 
temperature were regulated at a constant 52 ± 10 % and 22 ± 2 °C, respectively. Animals had 
free access to water and food. The amount ingested was recorded after periodic weighing of 
the leftover food. The study was approved by the Institutional Animal Care and Use 
Committee at the University of the Saarland. 
 
3 Dietary Intervention 
Basis of homocystine, methionine, and control diet was an herbal standard diet (Altromin 
C1100, Gesellschaft für Tierernährung GmbH, Deutschland) in pellet form. The purified 
control diet C1100 contained all essential food components in defined quantities. The content 
of B vitamins and energy were as follow: 
Vitamin B1: 18 mg/kg 
Vitamin B2: 12 mg/kg 
Vitamin B6: 9 mg/kg 
Vitamin B12: 0.024 mg/kg 
Folic acid: 2.904 mg/kg 
L-methionine: 3.772 g/kg (0.38%) 
Energy content: 2490 055 kcal/kg 
 
4 Narcotics 
The rats were anesthetized with a ketamin-rompun (1:0.24) mixture and dosed with 0.2 ml per 
100 mg bodyweight. Rompun (Bayer HealthCare®, Leverkusen, Germany) was available as 
2% and Ketamin (Pharmacia®, Erlangen, Germany) as 0.1 % solution. The intraperitoneal 
injection was administered in supine position and oblique head inclination.  
 
5 Collection of Blood and Tissue Samples 
Capillary blood from the retrobulbar venous plexus of the eye was collected before beginning 
the diet. Venous blood from the right ventricle of the heart was gathered at the end of the 
dietary intervention under anesthesia.  
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We isolated, sectioned the brain, and prepared the tissue samples for different purposes: 
measurement of SAH and SAM concentrations, as well as their ratios were determined in 
brain tissues, measurement of concentrations of phosphorylated Neurofilament H (pNF-H), 
tumor necrosis factor alpha (TNF-α), PP2A activity, in addition to protein expression of P-tau 
protein.  
First the rat brain and connecting proximal 2 mm brain stem were removed from the skull.  
  
  
Photo 2-5 
Tools and instruments used, dissection of rat brain, removal from skull, PBS rinsing 
 
Next the brain was rinsed in cooled PBS solution and weighed. Then each brain was 
immediately dissected with clean tools on a glass plate cooled on ice. The brain stem (S) was 
separated from the cerebellum, and the later was sectioned in median-sagital plane as shown 
in Photos 6 and 7.  
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Photos 3 and 4 
Sectioning of the brain 
 
The left (L) and right hemisphere were separated. Sagital and frontal plane sectioning divided 
the right hemisphere into quarters (R1, R2, R3, and R4). The (R2) of the right hemisphere was 
then sectioned in a frontal plane (R2WB and R2SH).  
Table 8 shows which methods were used and which parameter measured according to the 
different brain sections. 
 
Table 8 
Method, Parameter Brain sections Conservation Storage 
LC-Tandem-MS SAH/SAM 
measurement 
R2SH, S 0.1g brain tissue/ml acetic 
acid 1M, homogenized, 
mixed, sonicated on ice 10s 
Transfer to -80°C 
ELISA pNF-H, TNF-α R1 Snap frozen in screw 
eppendorfs on liquid 
nitrogen 
Transfer to -80°C 
ELISA PP2A activity, and 
total PP2A level 
R3 Snap frozen in screw 
eppendorfs on liquid 
nitrogen 
Transfer to -80°C 
Immunohistochemistry 
 P-tau 
L Immersed in 4% 
formaldehyde, parafinized 
Room temperature 
 
Abbreviations:  
R2SH: frontal lateral cortex section, S: brain stem, R1, R3: frontal medial cortex sections, L: left hemisphere 
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6 SAH and SAM Measurement in Brain Tissue and Plasma 
We used a modified stable-isotope dilution liquid chromatography tandem mass spectrometry 
method described by Kirsch et al (95). 
 
Preparation of brain tissue for SAH and SAM measurement: 
The frontal lateral R2SH and brain stem section S were used for SAH and SAM 
measurement. Tissue samples each weighing approximately 50 mg were immediately treated 
with cold 1 M acetic acid to a final concentration of 0.1 g tissue/ml (for 50 mg/500 µl acetic 
acid). Brain tissue was homogenized on ice in screw eppendorf containers. These 
homogenates were vortexed and sonicated on ice, five times 10 s each, and then frozen at –80 
°C. 
Acidified tissue samples were defrosted, mixed, and centrifuged at 879 g for 7 min (Sigma 3K 
12 Centrifuge®, West-Germany). Two hundred µl of the supernatants were then used for 
SAM/SAH assay. The supernatants were first prepared for solid phase extraction (SPE) for 
SAM/SAH assay as follows: 
Solid Phase extraction (SPE) was performed using a centrifuge 5810 R® (Eppendorf®, 
Hamburg, Germany) on a constant setting at 8 °C. SPE columns (Varian inc.®) containing 
phenylboronic acid, which specifically binds cis-diol groups at a pH of 7-8 were 
preconditioned by addition of 5 x 1 ml of mobile phase (4.24 M acetic acid, pH 2.636) and 5  
x 1 ml of wash buffer (20 mmol/l ammonium acetate, pH 7.42). Columns were centrifuged 
after each addition at 500 g for 1 min. Before SPE separation the acidified 200 µl tissue 
extracts were neutralized with 20 µl of 1 M ammonia to a pH of 7.4-7.5 and were mixed with 
50 µl of internal standards (3 µmol/l for ²H3-SAM and 0.8 µmol/l of ¹³C5-SAH) (labeled 
SAM: Dr. Ehrendorf GmbH®, Augsburg; labeled SAH: VU Medical Center®, Metabolic 
Laboratory, Amsterdam).  
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Photo 5-6 
Materials, Instruments used for SAH/SAM sample preparation 
 
Calibrators (SAM and SAH), high control, and low control were analyzed in each run. The 
stock solutions SAM 12.0 µmol/l and SAH 3.2 µmol/l were diluted with wash buffer (20 
mmol/l ammonium acetate, pH 7.42) to concentrations of 0, 750, 900, 1500, 1800 nmol/l for 
SAM and 0, 100, 200, 300, and 400 nmol/l for SAH as shown in Table 9. A high control of 
1500 nmol/l for SAM, 350 nmol/l for SAH and a low control at 800 nmol/l for SAM, and 150 
nmol/l for SAH were run each time to determine the coefficient of variations (CVs). 400 µl of 
each calibrator was mixed with 50 µl of internal standards and 40 µl wash buffer, the latter 
added for volume adjustment. The samples were mixed with 20 µl NH3 and 220 µl 
ammonium acetate for volume adjustment (Table 9). 
 
Table 9. SAH and SAM assay in brain tissue supernatants 
Calibrator SAM/SAH, 
in nmol/l 
and sample 
Volume of 
calibrator or 
sample, in µl 
Internal standard 
3 µmol/l 2H3-SAM and 0.8 
µmol/l 13C5-SAH, in µl 
20 mmol/l ammonium 
acetate (pH 7.42), 
in µl 
1 mmol/l 
ammonia NH3, 
in µl 
1800/400 400 50 40  
1500/300 400 50 40  
750/100 400 50 40  
0 0 50 440  
HC 1500/350 400 50 40  
LC 800/150 400 50 40  
Sample 200 50 220 20 
Abbreviations: HC: high control; LC: low control 
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The samples and calibrators were then applied to the SPE columns for binding of SAM, SAH, 
and their corresponding internal standards. Loaded columns were then centrifuged for 2 min 
at 250 g and then washed twice with 1 ml of the wash buffer, centrifuged for 1 min at 500 g to 
remove non-specifically bound compounds. SAH and SAM were eluted with 3 x 350 µl of 
mobile phase and centrifuged at 250 g for 2 min after each addition. After SPE the eluted 
samples containing SAH and SAM were either measured directly or stored for later assay 
with LCMS/MS at –80 °C. 
 
Liquid Chromatography Tandem Mass Spectrometer measurement 
Concentrations of SAH and SAM were measured on a Waters® 2795 Alliance HT HPLC 
System with a Micromass Quattro Micro API Tandem Mass Spectrometer. The mobile phase 
was aqueous acetic acid (pH 2,636) set to a flow rate of 0.3 ml/min. The samples (20 µl) were 
injected on SymmetryShield® RP18 Column (3.5 µm, 2.1x100 mm) with a corresponding 
Guard Column (3.5 µm, 2.1x10 mm) allowing the full injection of the sample into the 
electrospray injection chamber. Run time was 3 min per analysis. The retention times were 
1.99 min for SAH, 1.96 min for 
13
C5-SAH, 1.01 min for SAM, 0.98 min for 
2
H3-SAM. SAM 
and SAH concentrations were measured by multiple reaction monitoring (MRM) LC-ESI-
MS/MS in the positive-ion (ESI+) mode. The optimal conditions in ESI+ mode yielded 
following transitions: mass-to-charge ratio (m/z) 398.9 → 250.2 for SAM, m/z 402.9 → 250.2 
for 
2
H3-SAM, m/z 385.1 → 136.1 for SAH, and m/z 390.1 → 136.1 for 
13
C5-SAH. 
Concentrations of SAH and SAM were tested in acidified EDTA plasma samples just like in 
tissue samples (described above) with slight modifications (Table 10). 
 
Table 10. SAH and SAM assay in EDTA plasma sample, pool plasma: 103 nmol/l SAM, 15.6 nmol/l SAH 
Calibrator SAM/SAH, 
in nmol/l  
and sample 
Volume of calibrator 
or sample, in µl 
Internal standard 
3 µmol/l 2H3-SAM and 0.8 
µmol/l 13C5-SAH, in µl 
20 mmol/l ammonium 
acetate (pH 7.42), 
in µl 
1 mmol/l 
ammonia NH3, 
in µl 
200/48 400 50 40  
100/24 400 50 40  
50/12 400 50 40  
25/6 400 50 40  
0 0 50 440  
Pool Plasma 400 50 40 20 
EDTA plasma sample 400 50 40 20 
 
Kirsch et al. (95) compared  HPLC method with other studies. The determined concentrations 
of SAM and SAH obtained by Acquity UPLC BEH C18 column are comparable to the results 
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obtained by SymmetryShield RP18 with correlation coefficients (UPLC–MS/MS vs. HPLC–
MS/MS method) of r = 0.96 (SAH) and r = 0.83 (SAM). Mean SAM plasma concentrations 
(85.5 nmol/L) measured by UPLC–MS/MS method are in between those reported by 
Gellekink et al. (94.5 nmol/L) and Struys et al. (74.7 nmol/L). SAM plasma concentrations 
reported by Stabler et al. (109 nmol/L (71–168 nmol/L, 95% CI)) were approximately 22% 
higher. SAH plasma concentrations (13.3 nmol/L) are comparable with that obtained by 
Gellekink et al. (12.3 nmol/L), 13% lower than that obtained by Stabler et al. (15 nmol/L (8–
26 nmol/L, 95% confidence interval)) and approximately half of the concentration than that 
reported by Struys et al. (26.2 nmol/L) Precision was evaluated; inter-assay and intra-assay 
CVs <6 %. 
 
7 ELISA PNF-H, TNF-α, PP2A Activity and Level in Rat Brain Tissue 
Preparation of rat brain tissues for ELISA 
Brain samples from the frontal medial cortex sections R1 and R3 were collected in screw 
Eppendorf containers and immediately snap frozen in liquid nitrogen for several minutes and 
then transferred to –80 °C and stored.  
Later the R1 tissue samples were defrosted and homogenized in a buffer containing 4 M urea, 
1 mmol/l EDTA, 1 mmol/l EGTA, and 0.2 mmol/l PMSE in 10 mmol/l Tris-HCL at a pH of 
7.22. We used approximately 10 mg of wet weight of brain tissue per 1 ml buffer. After 
homogenization with insulin needles and sonication, the material was centrifuged in 
microfuge tubes for 5 minutes at top speed in an Eppendorf type centrifuge. We used 2 µl of 
homogenized CNS tissue for the ELISA. 
We used the sandwich ELISA for pNF-H (Chemicon International®) kit, Enzyme 
Immunoassay kit for TNF-α (assay designs® Catalog number: 900-086A), sandwich ELISA 
assay for PP2A activity in cell lysates (DuoSet IC® ELISA) from R&D System®. Total 
PP2A concentrations also measured using (DuoSet IC ELISA) from R&D System. 
The pNF-H assay system depends on using a 96-well plate coated with chicken polyclonal 
antibodies generated against pNF-H to capture pNF-H from the sample. Captured pNF-H is 
detected using pNF-H specific rabbit polyclonal antibodies and a goat anti-rabbit alkaline 
phosphatase conjugate. After addition of the substrate solution, the amount of pNF-H is 
determined. The standard curve demonstrates a direct relationship between optical density and 
pNF-H concentration. The calibration standards for pNF-H were set at 0.12, 0.23, 0.47, 0.94, 
1.86, 3.75, 7.5 ng/ml. Sensitivity: 0.0585 ng/ml. Range of Detection: 0.0293 ng/ml to 15 
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ng/ml. Total protein concentration in tissue extract was measured by using BCA method and 
pNF-H results were normalized for total protein. 
The TNF-α assay depends on using wells coated with a monoclonal antibody that binds rat 
TNF-α in the samples. A solution of biotinylated polyclonal antibody is added and binds to rat 
TNF-α. A solution of horseradish peroxidase (HRP) conjugate is added which binds to the rat 
TNF-α polyclonal. Tetramethylbenzidine (TMB) substrate solution is added. The substrate 
generates a blue color when catalyzed by HRP. Stop solution is added, and the resulting color 
is red at 450 nm. The standard curve demonstrates a direct relationship between optical 
density and TNF-α concentration. The calibration standards for TNF-α were 25, 31.3, 50, 
62.5, 100, 125, and 250 pg/ml. Specificity: There was no significant cross reactivity. 
Sensitivity was determined to be 12.0 pg/ml in Assay Buffer 28.  Inter-assay and intra-assay 
precision both had CVs <12%. 
The activity of PP2A was measured in brain frontal cortex samples using sandwich ELISA 
assay for rat PP2A activity in cell lysates (DuoSet IC ELISA) from R&D System®. For this 
assay, R3 brain sections were extracted by using 50 mmol/l HEPES, 0.1 mmol/l EGTA, 0.1 
mmol/l EDTA, 120 mmol/l NaCl, 0.5% NP-40 (pH 7.5), 25 µg/ml Leupeptin, 25 µg/ml 
Pepstatin, 2 µg/ml Aprotinin, 1 mmol/l PMSF. An immobilized capture antibody specific for 
the catalytic subunit C of PP2A binds both active and inactive PP2A. After washing out 
unbound material a synthetic phosphopeptide substrate is added. The phosphate release in the 
brain extract was then proportional to the active PP2A. This substrate is then 
dephosphorylated by active PP2A enabling the generation of free phosphate and 
unphosphorylated peptide. The free phosphate then is detected by a sensitive dye-binding 
assay using malachite green and molybdic acid. By calculating the rate of phosphate release, 
the activity of PP2A is determined and normalized to total protein content in the extract.  The 
Duoset IC activity is specific for PP2A and was demonstrated by Western blot analysis of 
protein immunoprecipitated with the anti-PP2A antibody supplied in the assay kit. 
Total PP2A concentrations were also measured in brain homogenesates using (DuoSet IC 
ELISA) from R&D System. The assay depends on using an immobilized capture antibody 
specific for the catalytic subunit of PP2A. After washing the unbound material, a biotinylated 
detection antibody specific for PP2A is used. The detection is completed using a standard 
Steptavidin-HRP system.   
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8 Biochemical Blood Analysis 
We analyzed concentrations of SAH, SAM, tHcy, folate, vitamin B12, and B6 in the rats’ 
plasma samples in the control and interventionary diets. The first sample was collected by 
extracting capillary blood from the retrobulbar venous plexus of the eye. The second sample 
was extracted by collecting venous blood from the right ventricle of the heart under 
anesthesia. 
 
9 Plasma SAH, SAM measurement 
Plasma SAH and SAM were selectively measured with our modified version of stable-isotope 
dilution liquid chromatography tandem mass spectrometry method described above in section 
5.2.  
 
10 Total Plasma Homocysteine Measurement 
Concentrations of tHcy were measured by enzymatic Fluorescence-Polarization-Immunoassay 
(FPIA) on an AxSYM® analysis device (Abbott®, Wiesbaden, Deutschland). This is a 
method used for routine use and suitable for laboratories requiring HCY high-output testing 
capabilities. The analytical performance of the AxSYM® tHcy FPIA has been compared to 
the well established high-performance liquid chromatography (HPLC) and IMx® tHcy FPIA 
methods and the two methods have corresponding mean differences. The method has been 
validated and compared to HPLC assay (107) and showed a correlation coefficient of r=0.985. 
Inter-assay and intra-assay precision both had CVs <5% according to protocol of National 
Committee for Clinical Laboratory Standards. 
 
11 Folate Measurement 
Folate was measured by competitive Chemilluminescence immunoassay on a Centaur® 
analysis device (Bayer Diagnostics®, Fernwald, Germany). To release folate bound to 
endogenous proteins, the sample is pretreated with a deliberation reagent. The folate in the 
sample competes with acridinium-marked folate in the reagent for a limited number of folate-
binding proteins covalently bound to paramagnetic particles. Finally these paramagnetic 
particles are washed and treated with a reagent leading to a Chemilluminescence reaction 
producing light. The intensity of this light reaction is inversely proportional to the folate 
concentration in the sample. The test used has been compared to the alternative method using 
chemilluminescence and showed a correlation coefficient of r=0.941. Traceability is 
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guaranteed by calibration to an internal standard which was produced by using highly purified 
N-5-methyltetrahydrofolate. Inter-assay and intra-assay precision both had CVs <8%. 
 
12 Vitamin B12 Measurement 
Vitamin B12 was measured by competitive Chemilluminescence immunoassay on a Centaur® 
analysis device (Bayer Diagnostics®, Fernwald, Germany). To release vitamin B12 bound to 
transcobalamins, the sample is pretreated with sodium hydroxide and dithiotrilae (DTT). The 
vitamin B12 in the sample competes with acridinium-marked vitamin B12 in the reagent for a 
limited amount of intrinsic factor covalently bound to paramagnetic particles. Finally these 
paramagnetic particles are washed. A starter reagent is added thereby activating the 
chemilluminescence reaction. The detected relative light units are inversely proportional to 
the concentration of vitamin B12.  The test used has been compared to the alternative method 
using ADS:180 VB12-test and showed a correlation coefficient of r=0.99. Traceability is 
guaranteed by calibration to an internal standard which was produced using material of the 
United States Pharmacopeia (USP). Inter-assay and intra-assay precision both had CVs <5%. 
 
13 Vitamin B6 (Pyridoxal-5’-Phosphate) Measurement  
Vitamin B6 was measured in the plasma on the Gynkotek® HPLC with an appropriate kit 
(Immundiagnostik®). The compositions of the flow agent, derivatisation, and precipitation 
reagent were not disclosed by Immundiagnostik.  The HPLC method is isocratic (constant 
composition of the mobile phase). A fluorescence detector was used to detect the signal. Intra-
assay and inter-assay CVs were <4.1%. 
 
14 Immunohistochemistry 
We isolated and sectioned the brain, as described above in 5. The left hemisphere was fixed in 
4% formalin. Then three parts of tissue (A, B, C) sectioned by transversal plane were 
embedded in paraffin. We chose the middle section B for our assay. To mount samples onto 
slides, silanization was necessary. In order to do this, slides were placed in acetone for 1 min, 
next in 2% silane in acetone (3-aminopropyl) triethoxysilane (Sigma® A-3648) for 1 min, 
dipped in acetone for 10 s and then dH2O for 10 s. The slides were dried overnight at 37 °C. 
We sectioned the middle section of the left hemisphere in transversal plane in slices of 5 µm 
thickness. The samples were floated atop a water bath to be rolled out and teased apart, 
always maintaining the same direction. Then the slices were transferred to a warm water bath 
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(50-55 °C) to smooth and stretch out the sample before floating the section onto the slide 
treated with silane. Slides then were dried in an oven at 60 °C overnight. For deparafinisation 
we first incubated the slides in two cuvettes filled with Xylene (Fluka® Cat NR 95692) five 
minutes each. Next the slides were moved into two cuvettes of 100 % Ethanol abs 
(Hedinger®) 3 min each. Slides were then incubated in 96 % Ethanol (2 min), 70 % Ethanol 
(2 min), 50 % Ethanol, dH2O (at least 30 s) and in PBS (10 min at room temperature), making 
sure not to dry out slides between transfers. 
The slides were incubated for 3 min in 1 mmol/l pH 6.0 citrate buffer in a plastic cuvette at 
560 W in a microwave accompanied by a plastic cuvette of dH2O to minimize evaporation.  
Incubation in microwave was repeated 7 times. 
For immunohistochemical stain we blocked unspecific bonds with 5% BSA in PBS for 30 
min. Then the slide was dried around the mounted sample, and a circle was carefully drawn 
with a paraffin marker. The samples were incubated with the first antibody (Mouse Anti 
Phospho Tau (ser396) 1:500 PBS (Invitrogen® Cat NR 355300) in a closed box lined with 
damp paper towels overnight at 4 °C. Next the slides were rinsed in PBS, and then washed 3 
times for 5 minutes each in a cuvette of PBS. Then samples were incubated with second 
antibody Alexa flour 488 goat anti mouse IgG 1:500 PBS (Invitrogen® Cat NR A-11001) for 
1 hour in the dark. The slides were washed again in PBS 3 times for 5 min. In the last step we 
trickled a drop of Mowiol on the slide, placed a cover glass on top, and let them dry overnight 
in the dark at room temperature. The fluorescence intensity in 4 independent photos from each 
section were calculated using AxioVision program from Carl Zeiss, and the mean of the 
intensities was considered for this section of a corresponding animal. 
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15 Reagents, Materials, and Instruments 
 
Reagent Company Catalog Number 
Herbal standard diet  Tierernährung GmbH, Deutschland Altromin C1100 
Ketamin (0.1% solution) Pharmacia®, Erlangen, Germany   
Rompun (2% solution) Bayer HealthCare®,  
Leverkusen, Germany  
 
Acetic Acid Aldrich® 338826 
Ammonium acetate Biosolve® 01244156 
Ammonia Merck® 1-05432.2500 
¹³C5-SAH  VU Medical Center®,  
Metabolic Laboratory, Amsterdam 
 
²H3-SAM Dr. Ehrendorf GmbH, Augsburg  
Urea Sigma® U-6504 
EDTA  
(ethylenedinitrilotetraacetic acid disodium salt dehydrate) 
Merck® 1.08418 
EGTA (ethylene glycol tetraacetic acid) Sigma® 095K5447 
PMSE (phenylmethylsulfonylfluoride) Sigma® P-7626 
Tris (hydroxymethyl) aminomethane Merck® 1.08382.1000 
Liquid nitrogen Air liquide®, Oberhausen  
Enzyme immunoassay kit for tumor necrosis factor alpha  
(TNF-α) 
Assay designs® 900-086A 
Phosphorylated neurofilament H  
(PNF-H) kit 
Chemicon International® NS170 
DuoSet IC® ELISA kit (PP2A activity) R&D System®  
DuoSet IC® ELISA kit (total PP2A concentration) R&D System®  
Dulbecco’s® Phosphate Buffered Saline (x1) PAA Laboratories® H21-002 
Formalin Fischar® 26053025 
Acetone Hedinger®  
Silane (3-Aminopropyltriethoxysilane) Sigma® A-3648 
Xylene Fluka® Cat NR 95692 
Ethanol abs Hedinger®  
1 mmol/l ph 6.0 Citrate Buffer Fluka® 82568 
BSA Sigma® A 7906-100G 
Paraffin marker Dako® S 200230-2 
Mouse Anti Phospho Tau (ser396) Invitrogen® Cat NR 355300 
Mouse APP (anti Alzheimer precursor protein A4)  Chemicon® Bat NR MAB348 
Polyclonal Rabbit Anti-Mouse Immunoglobulin/ HRP DakoCytomation® P0161 
2nd antibody (Alexa flour® 488 goat anti mouse IgG)  Invitrogen® Cat NR A-11001 
Mowiol Calbiochem® 9002-89-5 
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Instruments and Materials Company Manufactured in 
Vortex VF 2 Janke und Kunkel GmbH   
Sonicator 12 Bransonic®  
3K 12 Centrifuge  Sigma®  
5810 R Centrifuge Eppendorf® Hamburg, Germany 
Solid phase extraction columns containing phenylboronic acid Varian inc®  
HT 2795 HPLC System with a Micromass Quattro Micro API Tandem  
Mass Spectrometer 
Waters®  
Equilibrated (mobile phase) SymmetryShield® RP18 Column  
(3.5 µm, 2.1x100mm) 
Waters®  
Guard Column (3.5 µm, 2.1 x 10mm) Waters®  
Spectrometer Polarstar Optima® BMG Labtech®  
Microwave Panasonic®  
Microscope Axiovert® 40CFL Zeiss®  
ELISA Optical Densitometry Fluostar Optima®  
Immunofluorescence Densitometry Axio Vision® 4.4  
 
16 Statistics  
Data analyses were performed by using SPSS Version 18.0 (SPSS®, Chicago, USA). Results 
are shown as geometric mean (SD). Continuous variables were compared between the 3 
dietary groups using ANOVA test followed by Tamhane-T test when ANOVA was 
significant. Simple correlations between different parameters were tested using Spearman test. 
All p values <0.05 were considered statistically significant. 
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V Results  
 
1 Main Characteristics and Blood Markers Assayed in Plasma and Brain 
Main characteristics and blood markers in study animals at start are shown in Table 11. All 3 
group sizes were comparable. The control group consisted of 18 rats, homocystine group of 
19, and the methionine group was made up of 18 rats. All animals had a comparable starting 
body weight with a mean of 202 g. Folate concentration before dietary intervention was 277.4 
nmol/l (SD=61.1) for homocystine, 254.3 nmol/l (50.3) for methionine, and 311.7 nmol/l 
(48.3) for the control diet. Vitamin B12 concentration was 784.9 pmol/l (239.4) for 
homocystine, 1013.7 pmol/l (220.4) for methionine compared to 649.7 pmol/l (173.5) for the 
control diet.  Before randomization, the methionine group had significantly lower folate and 
higher plasma concentrations of vitamin B12 compared to the control group. However, plasma 
concentrations of tHcy were only slightly lower than the control group (mean 7.0 versus 8.8 
µmol/l; p=0.054) allowing this finding to be interpreted as coincidental. The concentrations of 
tHcy at start were not correlated to those of vitamin B12 or folate. Furthermore, concentrations 
of plasma folate and vitamin B12 in rats were negatively related before randomization (R=-
0.49, p=0.001). These unexpected correlations between folate and vitamin B12 might be 
related to differences in the content of the mother’s diet (before birth) or the rat’s diet shortly 
after birth. 
 
Table 11. Main characteristics and blood markers of study animals before dietary intervention 
 Control (n=18) Homocystine (n=19) Methionine (n=19) p 
     
Rat weight, in g 202.9 (9.3) 202.0 (9.6) 202.2 (8.1) 0.949 
Plasma tHcy, in µmol/l 8.8  (2.7) 7.2 (2.1) 7.0 (1.8)* 0.039 
Plasma folate, in nmol/l 311.7 (48.3) 277.4 (61.1) 254.3 (50.3)** 0.032 
Vitamin B12, in pmol/l 649.7 (173.5 ) 784.9 (239.4) 1013.7 (220.4)*** <0.001 
Data are geometric mean (standard deviation). *p=0.054 compared to control, **p=0.028 compared to 
control, and ***p<0.001 compared to control and homocystine groups. ANOVA followed by post-hoc 
Bonferroni test were applied. 
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Table 12 demonstrates the main characteristics and blood markers of study animals after 
dietary intervention according to diet. At the end of the 5 month dietary intervention, the rats 
from the homocystine group showed a significantly lower body weight mean (SD) 321.4 g 
(25.6), as did the animals from the methionine group 280.8 g (25.1) in comparison to the rats 
from the control diet 364.0 g (42.3). The weight of the brain after dietary intervention did not 
vary between the three groups 2.05 g (0.96) for the control group, 2.04 g (0.97) for the 
homocystine group, and 2.04 g (0.65) for the methionine group. Concentrations of tHcy were 
significantly increased after homocystine and methionine enriched diets over 5 months in 
comparison to the control diet. They caused a more than 10-fold increase in tHcy for 
homocystine diet and more than 15-fold increase for methionine diet.  
Moreover, homocystine and methionine enriched diets both showed a significant increase 
(p<0.05) for SAH and SAM and a significant reduction (p<0.05) of SAM/SAH ratio 
concentrations in the frontal cortex and brain stem as well as the plasma compared to 
concentrations found in the control rats. Effects in cerebral tissue are also shown in Figure 7. 
Surprisingly, though the dietary intervention was not vitamin deficient, the addition of 
homocystine and methionine for 5 months induced a higher folate turnover with lower folate 
plasma concentrations 192.6 nmol/l (34.9) for homocystine diet and 203.7 nmol/l (29.8) for 
methionine diet, compared to the control diet 222.5 nmol/l (41.8), as well as a significant 
reduction of vitamin B12 plasma concentration 492.6 pmol/l (64.8) for homocystine diet, 
459.5 pmol/l (69.9) for the methionine diet in comparison to 591.5 pmol/l (98.6) for control 
diet. 
Animals receiving the hyperhomocysteinemic diets showed a reduction in plasma vitamin B12 
concentrations compared to the control animals. The median difference between pre and post 
treatment of vitamin B12 was 75 pmol/l in the control, 218 pmol/l in the homocystine, and 620 
pmol/l in the methionine group. Plasma folate medians were lowered by 96 nmol/l in the 
control, 101 nmol/l in the homocystine, and 36 nmol/l in the methionine group when 
compared to baseline concentrations prior to dietary intervention. 
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Table 12. Main characteristics and blood markers of study animals after dietary intervention according to 
diet (1.7% homocystine diet and 2.4% methionine diet) 
 Control  
diet 
Homocystine 
diet 
Methionine  
diet 
p C-Hcy p C-Met p Met-Hcy 
       
Rat weight, in g 364.0 (42.3) 321.4 (25.6) 280.8 (25.1) <0.05 <0.05 <0.05 
Rat weight difference, in g 158.6 (40.1) 117.9 (24.0) 76.9 (20.9) <0.05 <0.05 <0.05 
Brain weight, in g 2.05 (0.96) 2.04 (0.97) 2.04 (0.65) n.s. n.s. n.s. 
Plasma tHcy, in µmol/l 7.0 (2.5) 74.4 (26.6) 112.9 (40.3) <0.001 <0.001 0.088 
Plasma folate, in nmol/l 222.5 (41.8) 192.6 (34.9) 203.7 (29.8) <0.05 >0.05 n.s. 
Plasma vitamin B12, in pmol/l 591.5 (98.6) 492.6 (64.8) 459.5 (69.9) 0.003 <0.001 0.382 
Plasma vitamin B6, in nmol/l 1474.5 
(542.7) 
1399.4 (452.7) 1264.8 (509.3) n.s. n.s. n.s. 
Plasma SAH, in nmol/l 18.5 (6.9) 172 (85) 494 (199) <0.05 <0.05 <0.05 
Plasma SAM, in nmol/l 270 (53) 266 (44) 712 (153) <0.05 <0.05 <0.05 
Plasma SAM/SAH ratio 14.6 (2.9) 1.5 (0.8) 1.4 (0.5) <0.05 <0.05 n.s. 
Frontal cortex SAH, in nmol/g 2.20 (0.36) 6.32 (1.32) 3.89 (1.85) <0.001 <0.001 0.001 
Frontal cortex SAM, in nmol/g 23.42 (4.62) 24.80 (3.15) 27.59 (12.7) 0.64 0.27 0.57 
Frontal cortex SAM/SAH ratio 10.65 (2.71) 3.92 (0.96) 7.09 (2.2) <0.001 <0.001 <0.001 
Brain stem SAH, in nmol/g 1.49 (0.56) 5.37 (1.97) 4.3 (3.05) <0.001 <0.001 0.46 
Brain stem SAM, in nmol/g 21.11 (10.3) 25.05 (3.94) 29.42 (8.78) 0.25 0.035 0.28 
Brain stem SAM/SAH ratio 14.2 (2.39) 4.67 (1.47) 6.85 (3.14) <0.001 <0.001 0.016 
All data are geometric mean (standard deviation). P-values: pC-Hcy testing for significance between control diet and 
homocystine diet, pC-Met between control diet and methionine diet, pMet-Hcy between methionine and homocystine. P 
according to ANOVA and post-hoc Tamhane-T test. The abbreviation n.s. stands for not significant.  
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2 Effect of Diets on Total Plasma Homocysteine in Rats 
Concentrations of tHcy were significantly increased after homocystine (n=19) and methionine 
(n=18) enriched diets over 5 months in comparison to the control diet (n=18). They caused 
more than a 10-fold increase in tHcy for homocystine and more than 15-fold increase for 
methionine diet. The medians were 86.2 µmol/l for the homocystine diet group, 129.8 µmol/l 
for the methionine group, and 6.8 µmol/l for the control group (Figure 6). 
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Figure 6 
Median (75th-25th percentile) plasma tHcy in rats according to diet after 5 months of dietary intervention. *p<0.05 
compared to controls (Mann-Whitney Test). 
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3 Effect of Diet on SAH, SAM, and SAM/SAH Ratio in Two Brain Regions 
Figure 7 shows median (75
th
-25
th
) percentiles of SAM, SAH, and their ratio in brain frontal 
cortex and brain stem according to the type of diet. Homocystine (n=19) and methionine 
(n=18) enriched diets showed a significant increase in SAH (p<0.05) and a significant 
reduction (p<0.05) of SAM/SAH ratio concentrations in brain stem and cortex compared to 
concentrations found in the corresponding brain area of the control rats (n=18). Median 
concentrations of SAH were 2.2 nmol/g for control group, 6.6 nmol/g for homocystine group, 
and 4.1 nmol/g for methionine group in the cortex. Median concentrations of SAH were 1.5 
nmol/g for control group, 5.4 nmol/g for homocystine group, and 4.3 nmol/g for methionine 
group in the brain stem. In the cortex median concentrations of SAM were 24.4 nmol/g for 
homocystine, 27.8 nmol/g for methionine, and 22.7 nmol/g for control.  In the brain stem 
there was a significant increase (p<0.05) 25.5 nmol/g for homocystine diet, 33.7 nmol/g for 
methionine diet, and 21.2 nmol/g for control diet (Figure 7). 
Median SAM/SAH ratio was 10.2 for control rats, 4.0 for homocystine group, and 7.7 for 
methionine group in the cortex. SAM/SAH ratio was 13.9 for control rats, 6.5 for 
homocystine group, and 4.7 for methionine diet in the brain stem.  
In the control and the homocystine fed animals, samples of brain stem showed lower 
concentrations of SAH compared to brain cortex. However comparable concentrations of 
SAM between the cortex and brain stem caused higher SAM/SAH ratio in the brain stem 
compared to the brain cortex. In contrast, in the methionine fed animals there were no 
significant differences in SAH, SAM, or their ratio between the frontal cortex and brain stem. 
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Figure 7 
Concentrations of SAH (A), SAM (B), and their ratio (C) per gram of rat brain tissue according to the type of diet. All 
data are median (75th-25th percentile), (*) p<0.05 compared to control group, (**) p<0.05 compared to homocystine 
and to control group.  frontal cortex,  brain stem. 
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4 Plasma Folate and Vitamin B12 and Association with Methylation Index 
As shown in Figure 8 plasma folate is positively correlated to methylation potential in the 
brain stem (Spearman correlation coefficient R=0.30, p=0.025) and the frontal cortex 
(R=0.36, p=0.007). In Figure 9 Plasma vitamin B12 is positively correlated to methylation 
potential reflected by SAM/SAH ratio in the brain stem (R=0.44, p=0.001) and the frontal 
cortex (R=0.37, p=0.006).  
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Figure 8 
Correlation between plasma folate and SAM/SAH ratio after dietary intervention (Spearman test). Total number of 
rats analyzed=55; О (circles); dotted line: frontal cortex,  (squares); continuous line: brain stem. 
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Figure 9 
Correlation between plasma vitamin B12 and SAM/SAH ratio after dietary intervention; Spearman test. Total 
number of rats analyzed=55; О (circles); dotted line: frontal cortex,  (squares); continuous line: brain stem. 
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5 Experimental Hyperhomocysteinemia and P-tau in Rat Brains 
We examined P-tau accumulation in frontal cortex from a total of 21 rats (9 controls, 6 methionine, 
and 6 homocystine). The median optical density measured in pixel in the frontal cortex of the 
left hemisphere probed with antibody against P-tau phosphorylated at serine 396 and then 
with a secondary antibody labeled with Alexa fluor® 488 was significantly (p<0.05) 
increased in rats receiving methionine (n=6) and homocystine (n=6) enriched diets over 5 
months in comparison to the control group (n=9) (Figure 10) (Photos 12-17). The methionine 
and homocystine-fed animals did not differ in P-tau(ser396) staining. We used Axio Vision® 
Rel 4.4 Carl Zeiss® computerized image analysis system. 
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Figure 10 
Optical density of P-tau immunofluorescence in brain tissue in pixel. Primary antibody was P-tau phosphorylated at 
serine 396. Measured with Axio Vision® Rel 4.4 Carl Zeiss®. * p<0.001 in comparison to control diet (ANOVA and 
Bonferroni tests). 
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Photos 12-17  
Representative sections in control diet group, homocystine, and methionine group in rat brain frontal cortex, left 
hemisphere. Fluorescence detection using P-tau at serine 396 and Alexa flour®, Axio Vision® Rel 4.4 Carl Zeiss® in 
all photos. 
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6 P-tau in Relation to Total Plasma Homocysteine and Plasma Folate 
Figure 11 shows the correlations between concentrations of plasma folate and tHcy and 
optical density in brain sections probed with antibody against P-tau phosphorylated at serine 
396 measured in pixel using Axio Vision® Rel 4.4 Carl Zeiss®. The staining of P-tau 
(quantitative optical density) correlated strongly and positively to plasma levels of tHcy (R= 
0.68, p=0.001, n=21) and negatively to plasma folate (R=-0.567, p=0.007, n=21). The 
correlations remained significant after adjusting for baseline metabolic markers (P-tau with 
tHcy R=0.68; and with folate R=- 0.76; p<0.01). Accumulation of P-tau in rat brain did not 
correlate to plasma concentrations of vitamin B6 or vitamin B12.  
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Figure 11  
Correlation between optical density (pixel) obtained from immunofluorescence microscope images of brain sections 
probed with antibody against P-tau (y-Axis), and plasma tHcy (R=0.68, p=0.001, n=21) on the left and plasma folate 
(R=-0.567, p=0.007, n=21) on the right. 
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7 TNF- , a Marker for Inflammatory Reaction 
The hyperhomocysteinemic diets had no significant effect on concentrations of TNF- 
extracted from the brain tissue (Figure 12). This indicates the diet did not induce an 
inflammatory reaction in brain tissues. 
 
 
 
 
Medians (75th-25th) percentiles of TNF- in rat brain frontal cortex according to the diet. No significant differences in 
concentrations were found between the rats according to the diet. The study included 55 rats.  Concentrations were 
not adjusted for total protein in the extracted tissues and measured by Enzyme Immunoassay kit for TNF-α (assay 
designs®). 
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8 PP2A Activity and Level in Extracts of Frontal Cortex  
We further studied the link between the metabolic conditions associated with HHCY and 
PP2A activity and/or level of PP2A protein in brain samples. Therefore, we tested the activity 
of the catalytic subunit of PP2A extracted from frontal cortex samples. Data on 
immunostaining for P-tau was available from 21 animals. Neither the activity of the active 
PP2A (the catalytic methylated subunit) when corrected for protein level nor the protein level 
itself of the catalytic subunit of PP2A differed according to diet (Table 13).  
 
Table 13. PP2A activity, level, and pNF-H of study animals after dietary intervention according to diet 
(1.7% homocystine diet and 2.4% methionine diet) 
 
Control 
diet 
Homocystine 
diet 
Methionine 
diet 
p C-
Hcy 
p C-
Met 
p Met-
Hcy 
PP2A activity, nmol phosphate 
relase/ng PP2A protein/30 min* 
13.6 (6.1) 12.1 (7.0) 12.7 (10.8) n.s. n.s. n.s. 
PP2A protein level, ng/mg protein* 1.24 (0.35) 1.05 (0.34) 1.07 (0.36) n.s. n.s. n.s. 
pNF-H, ng/mg protein* 0.53 (0.3) 0.73 (0.58) 3.47 (12.0) n.s. n.s. n.s. 
 
All data are geometric mean (standard deviation). P-values: pC-Hcy testing for significance between control diet and 
homocystine diet, pC-Met between control diet and methionine diet, pMet-Hcy between methionine and homocystine. P 
according to ANOVA and post-hoc Tamhane-T test. The abbreviation n.s. stands for not significant. * Marker 
measured in same extract of frontal cortex. 
 
We did observe a moderate negative correlation between PP2A activity in frontal cortex 
(expressed as nmol/µg protein/30min) and staining of P-tau protein (p=-0.51, p=0.013). Yet 
no significant correlation was found between PP2A activity of the methylated catalytic 
subunit when corrected for total catalytic PP2A level and P-tau. 
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Plasma folate, but not the type of diet or the methylation markers (in tissues or in plasma) was 
related to PP2A. According to this as demonstrated in Figure 13, we observed a weak positive 
correlation between PP2A activity of the methylated catalytic subunit corrected for total 
catalytic PP2A level and total protein and plasma folate (R=0.282, p=0.045, n=51). 
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Figure 13 
PP2A activity in relation to plasma folate (p=0.045) showing weak positive correlation (R=0.282) for n=51; corrected 
for total PP2A protein and total protein. 
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9 Phosphorylated Neurofilament H, a Marker of Axonal Degeneration  
We found no significant effect of the diet on concentrations of the marker for axonal 
degeneration, pNF-H, in brain tissues (Figure 14). Adjusting for total protein in the same 
extract of frontal cortex did not change the results (Table 13). 
 
 
Figure 14 
Medians (75-25th percentile) percentiles of pNF-H in rat brain frontal cortex according to diet. No significant 
differences in concentrations were found. The study included 55 rats. Concentrations of pNF-H adjusted for total 
protein in the extracted tissues and measured by ELISA (CHEMICON®). 
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10 PNF-H in Extracts of Frontal Cortex correlates with Folate 
We proposed that lower PP2A activity might be related to increased pNF-H because of the 
decrease in its dephosphorylation. Figure 15 demonstrates the negative significant correlation 
between pNF-H from brain extracts and plasma folate for the whole group (R=-0.30, p= 
0.031, n=52). When taking into consideration only the animals on the HHCY diets, pNF-H 
showed an even stronger negative correlation to plasma folate concentration (R=-0.46, 
p=0.005, n=36). PNF-H showed only a week negative correlation to the activity of the PP2A 
enzyme in brain tissues after correcting for PP2A protein level (R=-0.27, p=0.052, n=53), but 
a positive correlation with brain staining for P-tau (R=0.50, p=0.021, n=21).         
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Figure 15 
PNF-H in relation to plasma folate showing negative correlation (R=-0.30; p=0.031). 
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11 Ratio of P-Tau to PP2A activity in Relation to SAH, tHcy, and Folate 
We calculated the ratio of P-tau staining to PP2A activity per ng PP2A protein in the 21 
samples for which the immunohistochemistry results were available. Figure 16 shows strong 
correlations found between this ratio and plasma concentrations of SAH in brain cortex 
(R=0.53, p=0.019), tHcy (R=0.65, p=0.002), plasma folate (R=-0.63, p=0.003) 
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Figure 16 
The correlation between ratio of P-tau staining/PP2A activity per ng PP2A protein and brain cortex SAH, plasma 
tHcy and plasma folate in 21 rats (9 controls, 6 methionine, 6 homocystine). R is correlation coefficient according to 
Spearman test. 
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VI Discussion 
 
In the search for pathomechanisms that lead to neurodegeneration, in particular AD associated 
molecular abnormalities, much attention has been focused on micronutrients. Retrospective 
(21;32;33;102;205) as well as prospective clinical studies (46;112;132;146;165;181;212) have 
linked HHCY to neurodegenerative disease. However, treatment studies until now showed no 
consistent results, a causal relationship is therefore still outstanding. A possible link between 
impaired methylation and the etiology of AD has been proposed (169;188). The presumption 
is that HHCY is linked to neurodegenerative disease by mechanisms including 
hypomethylation. Vafai and Stock (169;188) were the first who suggested this link between 
impaired methylation and NFT formation. HHCY is known to cause lowered SAM, increased 
SAH concentrations, and therefore lowered SAM/SAH ratio. Several observational studies 
from cerebrospinal fluid and brain tissue of AD patients (91;124;134) support this view. An 
earlier report from 2007 found a negative association between concentrations or P-tau, folate 
and the SAH/SAM ratio in the CSF (134). The diet is one important source of methyl donors, 
therefore dietary recommendations for prevention of dementia could be an attractive 
approach. 
In our study homocystine and methionine diets fed to Wistar rats lead to a plasma tHcy 
elevation by more than 10-fold. Blood and brain concentrations of SAH and SAM were 
increased and their ratio lowered in rats fed a HHCY diet. Despite not using a diet deficient in 
folate or B-vitamins, animals fed with HHCY diets seemed to have higher requirements for 
folate and vitamin B12. Rats with higher plasma folate and plasma vitamin B12 concentrations 
showed a better methylation status. This was reflected by the positive correlation between 
plasma folate (R=0.36; p=0.007) (Figure 8) as well as plasma vitamin B12 (R=0.37; p=0.006) 
(Figure 9) and SAM/SAH ratio in two different brain regions. These results suggest that folate 
and/or vitamin B12 might increase availability of methyl groups in the brain. 
Our results are in accordance with one study by Sontag et al. (172) utilizing a folate deficient 
diet and another study by McCampbell et al. (113) using a methionine rich diet to generate 
HHCY in a mouse model. The magnitude of increase in concentrations of plasma tHcy and 
cerebral tissue SAH which we achieved by HHCY diets hardly differed in comparison. The 
concentrations of SAH, SAM and SAM/SAH ratio in brain tissue in rats nourished with our 
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control diet were similar to those on the control diet in the folate deficient mouse model 
described by Sontag et al. (172) 
Homocystine and methionine diets in Wistar rats lead to a plasma tHcy elevation by more 
than 10-fold and depletion of folate and vitamin B12. Both approaches leading to HHCY 
induced an impaired methylation status and folate depletion reflected by low SAM/SAH ratio 
in different brain areas. These animals showed an increased staining for P-tau in the frontal 
cortex compared to the control diet, and this may well be related to a disturbed methylation 
index. Our study demonstrated a negative correlation between plasma folate concentration 
and P-tau staining (R=- 0.76; p<0.01) even after adjusting for baseline metabolic markers. 
Vitamin deficient conditions can promote neurodegeneration (44;133;158;172) either via 
inducing hypomethylation, homocysteine, or a direct effect. For example in neuroblastoma 
cells, reduced methylation of PP2A (171) and PPMT activity (27) after SAH exposure or in a 
folate deficient medium (19) were reversible after adding SAM to the medium. PP2A can be 
demethylated by a methylesterase (PME-1) (136). PME-1 knock-out caused lower 
demethylation of PP2A but did not reduce cell death caused by folate deficiency (172). This 
suggests that folate deficiency has a unique mechanism inducing cell death. The negative 
relationship between folate on the one hand and P-tau or pNF-H on the other hand suggests 
that folate might protect against neurodegeneration by lowering protein phosphorylation. Our 
findings suggest that plasma tHcy and folate may be a predictor for the severity and/or 
progression of the accumulation of P-tau in the brain and higher blood folate might protect the 
brain from disorders in methyl group metabolism. This assumption is in agreement with the 
recent clinical study done by Oulhaj et al. in 2010 (138). 
In our study, SAH increase was associated with a substantial increase in SAM and a reduction 
of SAM/SAH ratio. The level and activity of the methylated catalytic subunit of PP2A were 
not lowered after our dietary intervention, but were negatively related to folate. 
Methyltransferases are inhibited either by decreased SAM concentrations or by increase of the 
competitive inhibitor SAH. In neuroblastoma cells adding SAH lowered PP2A methylation, 
and thereby substrate specificity (171). Moreover, mice fed on a high methionine/low folate 
diet had higher brain SAH and lower expression of PPMT thus leading to decrease of PP2A 
(171). Animal studies have shown that decreased methylated PP2A subunit in the brain 
tissues was associated with tau hyperphosphorylation (172). Clinical studies have been able to 
support this idea by showing that SAM was reduced in brain tissue and CSF in patients with 
AD (10;91;124;171). The role of SAM in dephosphorylation of tau suggests a relation 
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between plasma tHcy or folate and P-tau in the brain. Furthermore, an increase in 
concentration of SAH in AD patients was associated with lower activities in catechol-O-
methyltransferase and phenylethanolamine-N-methyltransferase (91). Other studies on AD 
brains have shown that the decrease in PP2A activity was related to a lower PP2A 
methylation and the expression of the regulatory subunit B of the enzyme (169). In addition, 
brains of patients with AD have shown lowered mRNA for PP2A (196), and elevated SAH 
suggesting a link between these conditions.  
Animals fed the homocystine and methionine diets in our study showed increased staining for 
P-tau. Our results revealed a positive correlation between plasma tHcy and optical density of 
P-tau accumulation in frontal cortex of cerebral tissue in rats (R=0.61, p=0.005). Recent in 
vivo studies are in accordance with our results. The study by Zhang et al. in 2008  (209) 
showed that high plasma tHcy induced by vena caudalis injection for 2 weeks was able to 
induce tau hyperphosphorylation at multiple sites in rat brain hippocampus. Folate and 
vitamin B12 supplementation lowered tHcy and tau phosphorylation in this animal model 
(209). In our study HHCY did not lead to changes in PP2A-mC activity or protein level of the 
total catalytic C subunit as listed in Table 13. In 2004 Sontag et al. proposed that the PP2A 
methylation system could be the link relating elevated plasma tHcy to Alzheimer disease 
(169). The enzyme PP2A is responsible for dephosphorylation of P-tau. It is likely that SAM-
dependant PP2A methyltransferase is inhibited by an increase in SAH hence impeding the 
degradation of P-tau protein. Zhang et al. (209) demonstrated how HCY induces tau 
phosphorylation by inhibiting the activity of PP2A and also activating methylesterase which 
stimulates demethylation of PP2A(C). In hippocampal slices of the HCY injected-rats and of 
the AD patients, the demethylated but not the methylated PP2A(C) was co-localized with the 
hyperphosphorylated tau. The study by Luo et al. in 2007 (110) investigated the effect of 
HCY on phosphorylation of tau by injecting HCY into the lateral cerebral ventricle of rats. 
They found that level of the hyperphosphorylated tau (ser396) was elevated prominently at 6, 
9, and 12 h after the injection, and recovered to normal at 24 h. Simultaneously, the level of 
PP2A catalytic subunit was reduced markedly when compared with control. The recent study 
by Sontag et al. (172) examined how folate deprivation over 8 weeks effects 
hyperphosphorylation of tau protein, PP2A enzyme, and the methyltransferase necessary for 
its activation. The folate deprived diet lead to disturbed methylation potential in cerebral 
tissue of mice and the involvement of downregulation of  the methyltransferase LCMT-1, and 
consequently the loss of ABαC (dominant brain isoform of protein phosphatase 2A) seems 
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related to tau phosphorylation and cell death. The authors were able to show that folate 
deficiency enhanced expression of non-methylated form of PP2A enzyme but was not able to 
change the methylation status of pre-existing PP2A suggesting that binding of B subunits to 
the methylated core enzyme stabilize it against demethylation by PME-1 (protein phosphatase 
methylesterase-1). However one in vitro study by Kuszczyk et al. is in contrast to the 
assumption that HHCY is a risk-factor for AD in which abnormal hyperphosphorylation of 
tau leads to neurofibrillary degeneration, and showed that acute exposure of primary rat 
cerebellar granule cell cultures to HCY at millimolar concentrations actually induced a 
glutamate receptor mediated decrease in tau phosphorylation (100). 
Taking into consideration different models that all shared similar metabolic conditions with 
increased SAH and reduced SAM (19;171) we proposed that the effect on P-tau protein was 
not directly related to tHcy increase.  Our results suggest that the accumulation of P-tau may 
be linked to elevation of SAH. Although SAH seems to act by binding the active sites of 
methyltransferases and thereby impeding SAM attachment and thereby inhibiting PP2A, this 
may be an oversimplification because many more factors seem to be involved. 
Recently, McCampbell et al. (113) used a high methionine diet or a folate deficient diet over 
the course of 10 weeks to induce HHCY. APP mice fed a high methionine diet but not those 
fed a folate deficient diet showed increased brain total tau and p-tau. No changes in either 
total or methylated PP2A protein were observed. In accordance with the results by 
McCampbell at al. we propose that the effect of the diet used in our study on P-tau was not 
directly related to decreased dephosphorylation of P-tau by PP2A. 
In general the accumulation of P-tau might be related to enhanced phosphorylation or 
decreased dephosphorylation (Figure 17). The interactive regulation of different kinase and 
phosphatase activities are thought to be a complex cellular process and alterations in PP2A 
activity are capable of affecting activity of protein kinases leading to changes in copious 
cellular functions (168). Increased P-tau under HHCY conditions without significant changes 
affecting PP2A suggests that P-tau accumulation might be related to enhanced formation 
mediated by augmentation of kinase pathways responsible for the phosphorylation in the 
brain. The effect of folate deficiency on P-tau-protein may be related to enhanced activity of 
different kinases involved in tau phosphorylation. The kinases’ activity seems to be sensitive 
to and inducted by calcium influx mediated via HCY-dependant activation of NMDA 
receptors (19). Another in vitro study (100) treated neurons acutely with HCY at neurotoxic 
concentrations. To reduce this effect an uncompetitive NMDA receptor antagonist was used 
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and a rapid decrease of P-tau staining was reported. This study demonstrates the link between 
NMDA receptor, a glutamate receptor, and P-tau accumulation. 
Hypomethylation seems to enhance abnormal tau phosphorylation by activation of glycogen 
synthase kinase 3 beta (GSK3beta) in addition to lowering PP2A (129). For example, 
GSK3beta gene expression and protein levels were increased under vitamin deficient 
conditions. This is in accordance with our finding on the positive correlation between P-tau 
and plasma folate and the reverse correlation between P-tau and plasma tHcy.  
Ho et al. demonstrated that increased tHcy or decreased folate concentrations in cultured 
neuron can promote tau phosphorylation (73) possibly mediated through oxidative stress via 
increased reactive oxygen species. Another explanation for P-tau increase without change in 
PP2A is protein-N-homocysteinylation that has been found to cause amyloid like protofibrils 
(139). P-tau might be N-homocysteinylated with HHCY causing PP2A to be unable to bind 
this substrate. This protein homocysteinylation might be the reason for a modification in 
substrate affinity of the enzyme. Furthermore, tau protein may be hyperphosphorylated at 
multiple sites causing the dissociation of this protein and the inability to bind to PP2A (170). 
The failure of interacting with phosphatases is a main pathomechanism in taupathies (31). 
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Figure 17 
Pathomechanisms affecting the phosphorylation of P-tau and pNF-H: Ca-dependent kinases phosphorylate tau and 
are enhanced by NMDA receptors, HHCY and SAH, PP2A activity can be enhanced by SAM and inhibited by SAH; 
Folate has a positive effect on dephosphorylation of P-tau.  
- 74 - 
 
PNF-H is an important protein involved in neurodegeneration. The majority of studies in the 
past have concentrated on hyperphosphorylation of tau as the major cytoskeletal pathology in 
AD. PNF-H though is also a component of aggregates in the AD brain (177;200). 
Our study documented a weak correlation between decreased PP2A activity and increased 
pNF-H concentrations. In one study, the inhibition of PP2A by ocaidic acid induced an 
increase in the pNF-H throughout the neuron showing that pNF-H is a substrate for PP2A 
(53). HHCY was not directly related to pNF-H. In our study however, plasma folate is 
lowered by supplementation of methionine or homocystine and this was related to increased 
pNF-H. Folate status seems to be a link to increased pNF-H in cerebral tissue, especially in 
rats subjected to HHCY diets. One study compared the pNF-H concentrations between AD 
and control tissues and reported a three-fold increase in pNF-H in AD tissue without increase 
in total NF-H levels or change in soluble (pin1) levels (140). The pin-1 enzyme may be a 
mediator for phosphorylation and methylation and thereby play a role in the formation of NFT 
(140). The pin-1 enzyme, one of the peptidyl-prolyl isomerases catalyzes the isomerisation of 
the peptide bond in proteins, thereby regulating their biological functions which include 
protein assembly, folding, intracellular transport, intracellular signalling, transcription, cell 
cycle progression and apoptosis and protects neurons under in vitro conditions. 
The significant reverse association between plasma folate and brain pNF-H levels remains 
unsolved and calls for further investigation. It has been reported that folate may have a 
protective effect on glutamate toxicity. If glutamate toxicity can lead to accumulation of pNF-
H in neuronal cells (140) this could suggest that a higher folate concentration might be 
capable of reducing pNF-H by decreasing the stimulation of the glutamate receptor mediated 
by HCY. 
In the current study HHCY and thereby perturbance in methylation was not related to the 
marker of inflammation TNF-, in cerebral tissue. TNF-α concentrations measured in rat 
cerebral tissue were similar when comparing control diet group with homocystine enriched 
and methionine enriched diet group. This suggests that inflammation does not function as an 
important neurotoxic modulator in HHCY. 
Our study results were in accordance with a study (3) with a small patient collective in which 
no significant difference in TNF-α concentrations in serum or CSF between AD patients and 
controls were found. In addition there was also no correlation in either subject group between 
the concentrations of these inflammatory mediators in serum or CSF, and the change in 
cognitive status or the progression of the atrophy of the medial temporal lobe. There seems to 
- 75 - 
 
be regional differences, reflected by concentrations of TNF-α in AD patients being 
significantly lower in the frontal cortex (32%, p = 0.024), the superior temporal gyrus (57%, p 
= 0.021), and the entorhinal cortex (49%, p = 0.009) compared with non-AD subjects. The 
fact that decreased cerebral concentrations of TNF-α are located in areas showing 
neuropathology in AD may indicate a dysregulation of the inflammatory process in AD. The 
large overlap between concentrations of TNF-α in AD patients and other subjects does not 
support the use of inflammatory mediators as predictive parameters for AD, also considering 
the poor relation to clinical signs of AD.  
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VII Conclusions 
 
 Homocystine and methionine enriched diets increased plasma tHcy by more than 10-
fold and effectively induced experimental HHCY in rats. 
 Homocystine and methionine diets led to a reduced methylation status reflected by 
SAH increase and SAM/SAH decrease in two different brain regions (frontal cortex 
and brain stem). 
 Plasma concentrations of folate and vitamin B12 significantly correlated to brain 
SAM/SAH ratio. Better B-vitamin status is directly related to better brain methylation 
status.  
 Homocystine and methionine diets caused P-tau accumulation both to a similar extent, 
in frontal cortex of rat brain. 
 P-tau accumulation in the frontal cortex is positively correlated to plasma tHcy and 
negatively correlated to plasma folate concentration. 
 P-tau accumulation could not be explained by changes in PP2A activity or PP2A 
protein level but by folate status. 
 Requirements and turnover of methyl groups are different according to brain region 
and may reflect different regional biochemical pathways. 
 Concentrations of pNF-H in frontal cortex did not differ according to diet.  
 Folate status was related to increased pNF-H in brain tissues from rats, especially 
those subjected to HHCY diet. 
 Concentrations of TNF-α in frontal cortex did not differ according to diet, so HCY 
neurotoxicity is not explained by inflammation in our study. 
 
Micronutrient deficiency is often a problem in the elderly population.  The role of HHCY and 
B-vitamin deficiency has been repeatedly demonstrated as a risk factor and prognostic factor 
for the development of dementia and other neurodegenerative diseases. Hence, enhancing 
status of methylation is promising when trying to counter metabolic changes related to the 
development of dementia. The experimental model inducing HHCY cannot be directly 
extrapolated to human beings without further research. Low serum folate is very common in 
elderly people and folate supplementation may form an early pathway to protect against 
dementia. Future studies should test in vivo the role of micronutrients like B-vitamins 
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especially folate and SAM in preventing or reversing P-tau accumulation in brain and/or the 
effect on pNF-H. Strategies aiming at arresting or reversing phosphorylation of tau or 
enhancing its dephosphorylation should consider long-term folate supplementation. 
Concentrations of tHcy that we achieved in our study were above the limits usually found in 
the general population and the exposure time was relatively short. Nevertheless, the 
development of dementia takes several decades to develop and even mild to moderate 
disturbances in the methyl group metabolism might be of importance. Future studies also 
might test the effect of mild or moderate HHCY over longer periods of time on P-tau 
accumulation and pNF-H. 
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